0000950170-22-015497 | 10-Q | XBRL Viewer | Allscripts Healthcare Solutions INC

Print Document View Excel Document

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Jun. 30, 2022	Aug. 01, 2022
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2022
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q2
Trading Symbol	MDRX
Entity Registrant Name	ALLSCRIPTS HEALTHCARE SOLUTIONS, INC.
Entity Central Index Key	0001124804
Entity Current Reporting Status	Yes
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Shell Company	false
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Common Stock, Shares Outstanding		110,792,560
Entity File Number	001-35547
Entity Tax Identification Number	36-4392754
Entity Address, Address Line One	222 Merchandise Mart
Entity Address, Address Line Two	Suite 2024
Entity Address, City or Town	Chicago
Entity Address, State or Province	IL
Entity Address, Postal Zip Code	60654
City Area Code	800
Local Phone Number	334-8534
Entity Interactive Data Current	Yes
Title of 12(b) Security	Common Stock, par value $0.01 per share
Security Exchange Name	NASDAQ
Entity Incorporation, State or Country Code	DE
Document Quarterly Report	true
Document Transition Report	false

CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 500,164	$ 132,517
Restricted cash	1,307	1,308
Accounts receivable, net of allowance of $12,581 and $13,360 as of June 30, 2022 and December 31, 2021, respectively	166,746	171,622
Contract assets, net of allowance of $564 and $576 as of June 30, 2022 and December 31, 2021	49,029	63,429
Prepaid expenses and other current assets	91,521	60,511
Assets held for sale	20,000	331,955
Total current assets attributable to discontinued operations	828,767	761,342
Fixed assets, net	14,971	9,819
Software development costs, net	82,541	74,688
Intangible assets, net	149,210	149,690
Goodwill	524,149	506,607
Deferred taxes, net	7	0
Contract assets - long-term, net of allowance of $1,201 and $1,534 as of June 30 2022 and December 31, 2021, respectively	19,358	28,174
Right-of-use assets - operating leases	15,904	18,324
Other assets	79,309	83,429
Long-term assets attributable to discontinued operations	0	793,156
Total assets	1,714,216	2,425,229
Current liabilities:
Accounts payable	18,014	5,281
Accrued expenses	82,964	54,518
Accrued compensation and benefits	34,001	31,055
Deferred revenue	84,882	120,748
Current operating lease liabilities	6,095	6,133
Current liabilities attributable to discontinued operations	30,372	329,347
Total current liabilities attributable to discontinued operations	256,328	547,082
Long-term debt	199,895	350,062
Deferred revenue	2,021	1,839
Deferred taxes, net	10,861	16,625
Long-term operating lease liabilities	13,873	16,754
Other liabilities	34,890	33,823
Long-term liabilities attributable to discontinued operations	0	50,906
Total liabilities	517,868	1,017,091
Commitments and contingencies
Stockholders’ equity:
Preferred stock: $0.01 par value, 1,000 shares authorized, no shares issued and outstanding as of June 30, 2022 and December 31, 2021	0	0
Common stock: $0.01 par value, 349,000 shares authorized as of June 30, 2022 and December 31, 2021; 279,175 and 110,793 shares issued and outstanding as of June 30, 2022, respectively; 276,705 and 116,114 shares issued and outstanding as of December 31, 2021, respectively	2,790	2,766
Treasury stock: at cost, 168,383 and 160,591 shares as of June 30, 2022 and December 31, 2021, respectively	(1,465,177)	(1,321,805)
Additional paid-in capital	1,923,805	1,962,386
Retained earnings	738,864	767,556
Accumulated other comprehensive loss	(3,934)	(2,765)
Total stockholders’ equity	1,196,348	1,408,138
Total liabilities and stockholders’ equity	$ 1,714,216	$ 2,425,229

CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Accounts receivable, allowance	$ 12,581	$ 13,360
Contract assets, allowance	564	576
Total contract assets, long-term	$ 1,201	$ 1,534
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	349,000,000	349,000,000
Common stock, shares issued	279,175,000	276,705,000
Common stock, shares outstanding	110,793,000	116,114,000
Treasury stock at cost, shares	168,383,000	160,591,000

CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Revenue:
Revenue from contract with customers	$ 150,898	$ 141,206	$ 293,570	$ 274,858
Cost of revenue:
Total cost of revenue	71,416	72,787	140,607	143,522
Gross profit	79,482	68,419	152,963	131,336
Selling, general and administrative expenses	59,847	28,124	101,165	60,288
Research and development	22,750	20,942	46,170	41,602
Asset impairment charges	0	172	0	172
Amortization of intangible and acquisition-related assets	2,241	2,363	4,412	4,727
(Loss) Income from operations	(5,356)	16,818	1,216	24,547
Interest expense	(1,887)	(2,949)	(4,023)	(6,092)
Other income, net	2,133	16,528	2,145	17,326
Equity in net loss of unconsolidated investments	(207)	(86)	(605)	(64)
(Loss) income from continuing operations before income taxes	(5,317)	30,311	(1,267)	35,717
Income tax benefit (provision)	(8,579)	4,168	(23,000)	5,274
Income from continuing operations, net of tax	3,262	26,143	21,733	30,443
Loss from discontinued operations	(3,797)	(6,178)	(8,818)	(358)
Gain on sale of discontinued operations	2,765	0	2,765	647
Income tax effect on discontinued operations	(66,256)	1,961	(56,849)	251
(Loss) income from discontinued operations, net of tax	(67,288)	(4,217)	(62,902)	540
Net (loss) income	$ (64,026)	$ 21,926	$ (41,169)	$ 30,983
Basic
Continuing operations	$ 0.03	$ 0.19	$ 0.19	$ 0.22
Discontinued operations	(0.59)	(0.03)	(0.55)	0.00
Net (loss) earnings per Common Share - Basic	(0.56)	0.16	(0.36)	0.22
Diluted
Continuing operations	0.03	0.18	0.17	0.21
Discontinued operations	(0.57)	(0.03)	(0.46)	0.00
Net (loss) earnings per Common Share - Diluted	$ (0.54)	$ 0.15	$ (0.29)	$ 0.21
Provider [Member]
Revenue:
Revenue from contract with customers	$ 118,939	$ 115,904	$ 237,604	$ 227,074
Cost of revenue:
Total cost of revenue	58,326	60,094	115,343	118,960
Payer & Life Sciences [Member]
Revenue:
Revenue from contract with customers	31,959	25,302	55,966	47,784
Cost of revenue:
Total cost of revenue	$ 13,090	$ 12,693	$ 25,264	$ 24,562

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Statement of Comprehensive Income [Abstract]
Net (loss) income	$ (64,026)	$ 21,926	$ (41,169)	$ 30,983
Other comprehensive income (loss):
Foreign currency translation adjustments	(717)	421	(867)	520
Change in fair value of derivatives qualifying as cash flow hedges	(153)	(828)	(404)	(1,509)
Other comprehensive (loss) income before income tax benefit	(870)	(407)	(1,271)	(989)
Income tax benefit related to items in other comprehensive income (loss)	38	214	102	390
Total other comprehensive income (loss)	(832)	(193)	(1,169)	(599)
Comprehensive income	$ (64,858)	$ 21,733	$ (42,338)	$ 30,384

- Definition

Amount before tax, after reclassification adjustments of other comprehensive income (loss).

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 5
-URI https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 45
-Paragraph 20
-URI https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 45
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=109237563&loc=d3e33775-111570

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 45
-Paragraph 17
-URI https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

+ Details

- Definition

Amount after tax and reclassification adjustments of other comprehensive income (loss).

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 45
-Paragraph 17
-URI https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 55
-Paragraph 15
-URI https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 45
-Paragraph 20
-URI https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 5
-URI https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

+ Details

- Definition

Amount of tax expense (benefit) allocated to other comprehensive income (loss).

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 20
-Section 45
-Paragraph 11
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=123586238&loc=d3e39076-109324

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 45
-Paragraph 17
-URI https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 45
-Paragraph 20
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 20
-Section 45
-Paragraph 2
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 10
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 12
-URI https://asc.fasb.org/extlink&oid=126968391&loc=d3e640-108580

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

+ Details

- Definition

The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (a)(1)
-URI https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 6
-URI https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 235
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-URI https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884

Reference 23: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (c)(1)
-URI https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 31: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4J
-URI https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686

Reference 32: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4K
-URI https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794

+ Details

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited) - USD ($) $ in Thousands	Total	Common Stock Issued [Member]	Treasury Stock [Member]	Additional Paid-In Capital [Member]	Additional Paid-In Capital [Member] Cumulative Effect Period Of Adoption Adjustment [Member] Revision Of Prior Period Accounting Standards Update Adjustment [Member]	Retained Earnings (Accumulated Deficit) [Member]	Retained Earnings (Accumulated Deficit) [Member] Cumulative Effect Period Of Adoption Adjustment [Member] Revision Of Prior Period Accounting Standards Update Adjustment [Member]	Accumulated Other Comprehensive Loss [Member]
Beginning Balance, Shares at Dec. 31, 2020		274,558,000	(134,616,000)
Beginning Balance at Dec. 31, 2020	$ 1,666,243	$ 2,745	$ (870,558)	$ 1,902,776		$ 633,118		$ (1,838)
Beginning Balance (ASU 2020-06 [Member]) at Dec. 31, 2020					$ 0		$ 0
Stock-based compensation				17,084
Ending Balance, Shares at Mar. 31, 2021		275,241,000	(134,616,000)
Ending Balance at Mar. 31, 2021	1,678,658	$ 2,751	$ (870,558)	1,906,534		642,175		(2,244)
Ending Balance (ASU 2020-06 [Member]) at Mar. 31, 2021					0		0
Beginning Balance, Shares at Dec. 31, 2020		274,558,000	(134,616,000)
Beginning Balance at Dec. 31, 2020	1,666,243	$ 2,745	$ (870,558)	1,902,776		633,118		(1,838)
Beginning Balance (ASU 2020-06 [Member]) at Dec. 31, 2020					0		0
Common stock issued under stock compensation plans, net of shares withheld for employee taxes, Shares		2,110,000
Common stock issued under stock compensation plans, net of shares withheld for employee taxes		$ 21		(13,912)
Issuance of treasury stock, Shares			33,000
Treasury Stock, Shares, Acquired			6,397,000
Issuance of treasury stock	534		$ 465	69
Purchase of treasury stock, Shares			(6,397,000)
Purchase of treasury stock			$ (108,953)
Accelerated share repurchase program, Shares			10,677,000
Accelerated share repurchase program			$ (195,452)	(4,548)
Warrants issued				2,073
Net (loss) income						30,983
Foreign currency translation adjustments, net	520							520
Unrecognized loss on derivatives qualifying as cash flow hedges, net of tax								(1,119)
Ending Balance, Shares at Jun. 30, 2021		276,668,000	(151,657,000)
Ending Balance at Jun. 30, 2021	1,393,474	$ 2,766	$ (1,174,498)	1,903,542		664,101		(2,437)
Beginning Balance, Shares at Dec. 31, 2020		274,558,000	(134,616,000)
Beginning Balance at Dec. 31, 2020	$ 1,666,243	$ 2,745	$ (870,558)	1,902,776		633,118		(1,838)
Beginning Balance (ASU 2020-06 [Member]) at Dec. 31, 2020					0		0
Common stock issued under stock compensation plans, net of shares withheld for employee taxes, Shares	2,200,000
Ending Balance, Shares at Dec. 31, 2021	276,705,000	276,705,000	(160,591,000)
Ending Balance at Dec. 31, 2021	$ 1,408,138	$ 2,766	$ (1,321,805)	1,962,386		767,556		(2,765)
Ending Balance (ASU 2020-06 [Member]) at Dec. 31, 2021					(38,918)		12,477
Beginning Balance, Shares at Mar. 31, 2021		275,241,000	(134,616,000)
Beginning Balance at Mar. 31, 2021	1,678,658	$ 2,751	$ (870,558)	1,906,534		642,175		(2,244)
Beginning Balance (ASU 2020-06 [Member]) at Mar. 31, 2021					0		0
Stock-based compensation				8,383
Common stock issued under stock compensation plans, net of shares withheld for employee taxes, Shares		1,427,000
Common stock issued under stock compensation plans, net of shares withheld for employee taxes		$ 15		(7,932)
Issuance of treasury stock, Shares			33,000
Treasury Stock, Shares, Acquired			6,397,000
Issuance of treasury stock			$ 465	69
Purchase of treasury stock, Shares			(6,397,000)
Purchase of treasury stock			$ (108,953)
Accelerated share repurchase program, Shares			10,677,000
Accelerated share repurchase program			$ (195,452)	(4,548)
Warrants issued				1,036
Net (loss) income						21,926
Foreign currency translation adjustments, net	421							421
Unrecognized loss on derivatives qualifying as cash flow hedges, net of tax								(614)
Ending Balance, Shares at Jun. 30, 2021		276,668,000	(151,657,000)
Ending Balance at Jun. 30, 2021	$ 1,393,474	$ 2,766	$ (1,174,498)	1,903,542		664,101		(2,437)
Beginning Balance, Shares at Dec. 31, 2021	276,705,000	276,705,000	(160,591,000)
Beginning Balance at Dec. 31, 2021	$ 1,408,138	$ 2,766	$ (1,321,805)	1,962,386		767,556		(2,765)
Beginning Balance (ASU 2020-06 [Member]) at Dec. 31, 2021					(38,918)		12,477
Stock-based compensation				19,952
Accounting Standards Update [Extensible List]	Stock-based compensation
Ending Balance, Shares at Mar. 31, 2022		277,696,000	(162,904,000)
Ending Balance at Mar. 31, 2022	$ 1,353,106	$ 2,776	$ (1,371,484)	1,922,026		802,890		(3,102)
Ending Balance (ASU 2020-06 [Member]) at Mar. 31, 2022					0		0
Beginning Balance, Shares at Dec. 31, 2021	276,705,000	276,705,000	(160,591,000)
Beginning Balance at Dec. 31, 2021	$ 1,408,138	$ 2,766	$ (1,321,805)	1,962,386		767,556		(2,765)
Beginning Balance (ASU 2020-06 [Member]) at Dec. 31, 2021					(38,918)		12,477
Common stock issued under stock compensation plans, net of shares withheld for employee taxes, Shares	2,500,000	2,470,000
Common stock issued under stock compensation plans, net of shares withheld for employee taxes		$ 24		(27,910)
Issuance of treasury stock, Shares			0
Treasury Stock, Shares, Acquired			7,792,000
Issuance of treasury stock	$ 0		$ 0	0
Purchase of treasury stock, Shares			(7,792,000)
Purchase of treasury stock			$ (143,372)
Accelerated share repurchase program, Shares			0
Accelerated share repurchase program			$ 0	0
Warrants issued				8,295
Net (loss) income						(41,169)
Foreign currency translation adjustments, net	$ (867)							(867)
Unrecognized loss on derivatives qualifying as cash flow hedges, net of tax								(302)
Ending Balance, Shares at Jun. 30, 2022	279,175,000	279,175,000	(168,383,000)
Ending Balance at Jun. 30, 2022	$ 1,196,348	$ 2,790	$ (1,465,177)	1,923,805		738,864		(3,934)
Beginning Balance, Shares at Mar. 31, 2022		277,696,000	(162,904,000)
Beginning Balance at Mar. 31, 2022	1,353,106	$ 2,776	$ (1,371,484)	1,922,026		802,890		(3,102)
Beginning Balance (ASU 2020-06 [Member]) at Mar. 31, 2022					$ 0		$ 0
Stock-based compensation				9,129
Common stock issued under stock compensation plans, net of shares withheld for employee taxes, Shares		1,479,000
Common stock issued under stock compensation plans, net of shares withheld for employee taxes		$ 14		(14,608)
Issuance of treasury stock, Shares			0
Treasury Stock, Shares, Acquired			5,479,000
Issuance of treasury stock			$ 0	0
Purchase of treasury stock, Shares			(5,479,000)
Purchase of treasury stock			$ (93,693)
Accelerated share repurchase program, Shares			0
Accelerated share repurchase program			$ 0	0
Warrants issued				7,258
Net (loss) income						(64,026)
Foreign currency translation adjustments, net	$ (717)							(717)
Unrecognized loss on derivatives qualifying as cash flow hedges, net of tax								(115)
Ending Balance, Shares at Jun. 30, 2022	279,175,000	279,175,000	(168,383,000)
Ending Balance at Jun. 30, 2022	$ 1,196,348	$ 2,790	$ (1,465,177)	$ 1,923,805		$ 738,864		$ (3,934)

CONSOLIDATED STATEMENTS OF STOCKHOLDERS EQUITY (Parenthetical)	Jun. 30, 2022	Jun. 30, 2020	Dec. 31, 2019
0.875% Convertible Senior Notes [Member]
Debt Instrument, Interest Rate, Stated Percentage	0.875%	0.875%	0.875%

CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Cash flows from operating activities:
Net (loss) income	$ (41,169)	$ 30,983
Less: (Loss) income from discontinued operations	(62,902)	540
Income from continuing operations	21,733	30,443
Adjustments to reconcile net (loss) income to net cash provided by (used in) operating activities:
Depreciation and amortization	28,465	32,940
Non-cash lease expense, net	(5,186)	(5,649)
Stock-based compensation expense	15,348	4,822
Deferred taxes	(467)	5,772
Impairment of assets and long-term investments	0	172
Equity in net loss of unconsolidated investments	605	64
Other (income) loss, net	(1,354)	43
Changes in operating assets and liabilities (net of businesses acquired):
Accounts receivable and contract assets, net	28,751	11,814
Prepaid expenses and other assets	10,248	(4,513)
Accounts payable	25,246	1,422
Accrued expenses	12,440	37,725
Accrued compensation and benefits	(3,215)	(10,421)
Deferred revenue	(35,156)	(20,526)
Other liabilities	(20,798)	4,145
Net cash provided by operating activities - continuing operations	76,660	88,253
Net cash provided by (used in) operating activities - discontinued operations	(9,034)	(284,615)
Net cash provided by (used in) operating activities	67,626	(196,362)
Cash flows from investing activities:
Capital expenditures	(1,652)	(225)
Capitalized software	(18,258)	(16,735)
Cash paid for business acquisitions, net of cash acquired	(24,106)	0
Sale of businesses and other investments, net of cash divested, and distributions received	672,488	4,242
Purchases of equity securities, other investments and related intangible assets, net	(251)	(221)
Net cash provided by (used in) investing activities - continuing operations	628,221	(12,939)
Net cash used in investing activities - discontinued operations	(15,248)	(21,606)
Net cash provided by (used in) investing activities	612,973	(34,545)
Cash flows from financing activities:
Taxes paid related to net share settlement of equity awards	(27,871)	(12,638)
Credit facility payments	(200,000)	0
Credit facility borrowings, net of issuance costs	22,335	250,000
Repurchase of common stock	(143,372)	(308,953)
Intercompany to/from parent/subsidiaries	11,685	4,987
Payment of acquisition and other financing obligations	0	(2,400)
Net cash used in financing activities - continuing operations	(337,223)	(69,004)
Net cash used in financing activities - discontinued operations	(11,697)	(6,236)
Net cash used in financing activities	(348,920)	(75,240)
Effect of exchange rate changes on cash and cash equivalents	(728)	65
Net increase (decrease) in cash and cash equivalents	330,951	(306,082)
Cash, cash equivalents and restricted cash, beginning of period	190,520	537,465
Cash, cash equivalents and restricted cash, end of period	521,471	231,383
Less: Cash and cash equivalents attributable to discontinued operations	(20,000)	(70,520)
Cash, cash equivalents and restricted cash, end of period, excluding discontinued operations	$ 501,471	$ 160,863

Basis of Presentation and Significant Accounting Policies	6 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
Basis of Presentation and Significant Accounting Policies	1. Basis of Presentation and Significant Accounting Policies Principles of Consolidation The consolidated financial statements include the accounts of Allscripts Healthcare Solutions, Inc. (“Allscripts”) and its wholly-owned subsidiaries and controlled affiliates. All significant intercompany balances and transactions have been eliminated. Each of the terms “we,” “us,” “our” or the “Company” as used herein refers collectively to Allscripts Healthcare Solutions, Inc. and its wholly-owned subsidiaries and controlled affiliates, unless otherwise stated. Unaudited Interim Financial Information The unaudited interim consolidated financial statements as of and for the three and six months ended June 30, 2022 and 2021 have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (the “SEC”) for interim financial reporting. These interim consolidated financial statements are unaudited and, in the opinion of our management, include all adjustments, consisting of normal recurring adjustments and accruals, necessary to present fairly the consolidated financial statements for the periods presented in accordance with generally accepted accounting principles in the United States of America (“GAAP”). The consolidated results of operations for the three and six months ended June 30, 2022 are not necessarily indicative of the results to be expected for the full year ending December 31, 2022. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with GAAP have been condensed or omitted in accordance with the SEC's rules and regulations for interim reporting. The Company believes that the disclosures made are adequate to make these unaudited interim consolidated financial statements not misleading. They should be read in conjunction with the consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended December 31, 2021, as amended (our “Form 10-K”). Use of Estimates The preparation of consolidated financial statements in accordance with GAAP requires us to make estimates and assumptions that affect the amounts reported and disclosed in the consolidated financial statements and the accompanying notes. Our estimates and assumptions consider the current macroeconomic trends and their implications of COVID-19 on our critical and significant accounting estimates. Actual results could differ materially from these estimates. Significant Accounting Policies There have been no changes to our significant accounting policies from those disclosed in our Form 10-K. Recently Adopted Accounting Pronouncements In August 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2020-06, “Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity” (“ASU 2020-06”). The amendments in ASU 2020-06 simplify the accounting for convertible instruments by removing major separation models required under current GAAP. ASU 2020-06 removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exceptions and also requires the application of the if-converted method for calculating diluted earnings per share, whereas the treasury stock method is no longer permitted for convertible instruments. The standard is effective for public business entities, excluding entities eligible to be smaller reporting companies as defined by the SEC, for fiscal years and interim periods within those fiscal years, beginning after December 15, 2021. We adopted ASU 2020-06 on January 1, 2022 using the modified retrospective method of transition, which resulted in an increase in long-term debt of $26.4 million, a decrease in additional paid-in capital of $38.9 million and an increase to retained earnings of $12.5 million, as of January 1, 2022. Refer to Note 10, “Debt” for additional information. Accounting Pronouncements Not Yet Adopted In October 2021, the FASB issued Accounting Standards Update No. 2021-08, “Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers” (“ASU 2021-08”), which requires contract assets and contract liabilities (deferred revenue) acquired in a business combination to be recognized and measured by the acquirer on the acquisition date in accordance with Accounting Standards Codification (“ASC”) 606, “Revenue from Contracts with Customers”, as if it had originated the contracts. The new guidance creates an exception to the general recognition and measurement principles of ASC 805, “Business Combinations”. The new standard should be applied prospectively and is effective for all public business entities for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. The standard is effective for all other entities for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted. We are currently evaluating the effects of the adoption of ASU 2021-08 on our consolidated financial statements. We do not believe that any other recently issued, but not yet effective accounting standards, if adopted, will have a material impact on our consolidated financial statements.

Revenue from Contracts with Customers

6 Months Ended

Jun. 30, 2022

Revenue from Contract with Customer [Abstract]

Revenue from Contracts with Customers

2. Revenue from Contracts with Customers

Our two primary revenue streams are (i) provider revenue and (ii) payer and life sciences revenue. Provider revenue consists of revenue derived from software applications for patient engagement and the sale of EHR software to single-specialty and small and mid-sized physician practices, including related clinical, financial, administrative and operational solutions. Payer and life sciences revenue primarily consists of sales of our integrated data systems solutions and related services to key healthcare stakeholders, including health plans and pharmaceutical companies, to help them improve the quality, efficiency and value of healthcare delivery.

At June 30, 2022 and December 31, 2021, we had capitalized costs to obtain or fulfill a contract of $10.2 million and $8.1 million, respectively, in Prepaid and other current assets and $11.9 million for each in Other assets. During both the three months ended June 30, 2022 and 2021, we recognized $2.9 million of amortization expense related to such capitalized costs. During the six months ended June 30, 2022 and 2021, we recognized $5.8 million and $6.2 million, respectively, of amortization expense related to such capitalized costs. The amortization of these capitalized costs to obtain a contract are included in Selling, general and administrative expense within our consolidated statements of operations.

The timing of revenue recognition, billings and cash collections results in billed and unbilled accounts receivable, contract assets and customer advances and deposits. Accounts receivable, net includes both billed and unbilled amounts where the right to receive payment is unconditional and only subject to the passage of time. Contract assets include amounts where revenue recognized exceeds the amount billed to the customer and the right to payment is not solely subject to the passage of time. Deferred revenue includes advanced payments and billings in excess of revenue recognized. Our contract assets and deferred revenue are reported in a net position on an individual contract basis at the end of each reporting period. Contract assets are classified as current or long-term based on the timing of when we expect to complete the related performance obligations and bill the customer. Deferred revenue is classified as current or long-term based on the timing of when we expect to recognize revenue.

The breakdown of revenue recognized based on the origination of performance obligations and elected accounting expedients is presented in the tables below:


(In thousands)	Three Months Ended March 31, 2022		Three Months Ended June 30, 2022
Revenue related to deferred revenue balance at beginning of period	$	36,151	$	25,901
Revenue related to new performance obligations satisfied during the period		45,306		55,990
Revenue recognized under "right-to-invoice" expedient		61,114		68,877
Reimbursed travel expenses, shipping and other revenue		101		130
Total revenue	$	142,672	$	150,898


(In thousands)	Three Months Ended March 31, 2021		Three Months Ended June 30, 2021
Revenue related to deferred revenue balance at beginning of period	$	29,401	$	36,770
Revenue related to new performance obligations satisfied during the period		47,263		41,814
Revenue recognized under "right-to-invoice" expedient		56,811		62,105
Reimbursed travel expenses, shipping and other revenue		177		517
Total revenue	$	133,652	$	141,206

The aggregate amount of contract transaction price related to remaining unsatisfied performance obligations represents contracted revenue that has not yet been recognized and includes both deferred revenue and amounts that will be invoiced and recognized as revenue in future periods. Total unsatisfied performance obligations equaled $923 million as of June 30, 2022, of which we expect to recognize approximately 29% over the next 12 months, and the remaining 71% thereafter.

Revenue Recognition

We recognize revenue only when we satisfy an identified performance obligation (or bundle of obligations) by transferring control of a promised product or service to a customer. We consider a product or service to be transferred when a customer obtains control because a customer has sole possession of the right to use (or the right to direct the use of) the product or service for the remainder of its economic life or to consume the product or service in its own operations. We evaluate the transfer of control primarily from the customer’s perspective as this reduces the risk that revenue is recognized for activities that do not transfer control to the customer.

The majority of our revenue is recognized over time because a customer continuously and simultaneously receives and consumes the benefits of our performance. The exceptions to this pattern are our sales of perpetual and term software licenses, and hardware, where we determined that a customer obtains control of the asset upon granting of access, delivery or shipment.

We disaggregate our revenue from contracts with customers based on the type of revenue and nature of revenue stream, as we believe those categories best depict how the nature, amount and uncertainty of our revenue and cash flows are affected by economic factors. The tables below summarize revenue by type and nature of revenue stream as well as by our reportable segment.


	Three Months Ended June 30, 2022
(In thousands)	Veradigm		Unallocated Amounts		Total
Provider	$	112,678	$	6,261	$	118,939
Payer & Life Sciences		31,959		0		31,959
Total revenue	$	144,637	$	6,261	$	150,898


	Three Months Ended June 30, 2021
(In thousands)	Veradigm		Unallocated Amounts		Total
Provider	$	108,147	$	7,757	$	115,904
Payer & Life Sciences		25,302		0		25,302
Total revenue	$	133,449	$	7,757	$	141,206


	Six Months Ended June 30, 2022
(In thousands)	Veradigm		Unallocated Amounts		Total
Provider	$	224,949	$	12,655	$	237,604
Payer & Life Sciences		55,966		0		55,966
Total revenue	$	280,915	$	12,655	$	293,570


	Six Months Ended June 30, 2021
(In thousands)	Veradigm		Unallocated Amounts		Total
Provider	$	212,035	$	15,039	$	227,074
Payer & Life Sciences		47,784		0		47,784
Total revenue	$	259,819	$	15,039	$	274,858

Contract Assets – Estimate of Credit Losses

We adopted Accounting Standards Update No. 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”) on January 1, 2020 using the cumulative-effect adjustment transition method. The guidance required the recognition of lifetime estimated credit losses expected to occur for contract assets and trade receivables. The guidance also required that we pool assets with similar risk characteristics and consider current economic conditions when estimating losses.

We segmented the contract asset population into pools based on their risk assessment. Risks related to contract assets are a customer’s inability to pay or bankruptcy. Each pool was defined by their internal credit assessment and business size. We also used each customer’s primary business unit in our pooling determination. This assessment provides information of the customer including size, segment and industry. The pools are aligned with management’s current review of financial performance. For the three and six months ended June 30, 2022, no adjustment to the pools was necessary.

We utilized a loss-rate method to measure expected credit loss for each pool. The loss rate is calculated using a 24-month lookback period of credit memos and adjustments divided by the average contract asset balance for each pool during that period. We considered current economic conditions, including macroeconomic and inflationary trends and how the COVID-19 pandemic is impacting the global economy, internal forecasts, cash collection and credit memos written during the current period when assessing loss rates. We reviewed these factors and concluded that no adjustments should be made to the historical loss rate data. The June 30, 2022 analysis resulted in a reduction to the ending estimate of credit losses.

Changes in the estimate of credit losses for contract assets are presented in the table below.


	Six Months Ended June 30,
(In thousands)	2022			2021
Beginning balance	$	2,110		$	2,110
Write-offs		(345	)		0
Ending balance	$	1,765		$	2,110
Less: Contract assets, short-term		564			576
Total contract assets, long-term	$	1,201		$	1,534

- Definition

The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-URI https://asc.fasb.org/topic&trid=49130388

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 10
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)(2)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 9
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (e)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 15
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045

+ Details

Accounts Receivable

6 Months Ended

Jun. 30, 2022

Receivables [Abstract]

Accounts Receivable

3. Accounts Receivable

Trade Accounts Receivable – Estimate of Credit Losses

We adopted ASU 2016-13 on January 1, 2020 using the cumulative-effect adjustment transition method. Refer to Note 2, “Revenue from Contracts with Customers” for information regarding the adoption of ASU 2016-13. No adjustments were made to the pools or historical loss rate data for trade accounts receivable during the six months ended June 30, 2022.

Changes in the estimate of credit losses for trade accounts receivable are presented in the table below.


	Six Months Ended June 30,
(In thousands)	2022			2021
Beginning balance	$	13,360		$	20,228
Current period provision		298			539
Write-offs		(1,077	)		(1,021	)
Ending balance	$	12,581		$	19,746

Leases

6 Months Ended

Jun. 30, 2022

Lessee Disclosure [Abstract]

Leases

4. Leases

We determine whether an arrangement is a lease at inception. Assets leased under an operating lease arrangement are recorded in Right-of-use assets – operating leases and the associated lease liabilities are included in Current operating lease liabilities and Long-term operating lease liabilities within the consolidated balance sheets. Assets leased under finance lease arrangements are recorded within fixed assets and the associated lease liabilities are recorded within Accrued expenses and Other liabilities within the consolidated balance sheets.

Right-of-use assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease right-of-use assets and liabilities are recognized at the commencement date based on the present value of lease payments over the expected lease term. Since our lease arrangements do not provide an implicit rate, we use our incremental borrowing rate in conjunction with the market swap rate for the expected remaining lease term at the commencement date for new leases in determining the present value of future lease payments. Our expected lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term.

We have elected the group of practical expedients under Accounting Standards Update No. 2016-02, Leases (Topic 842) (“ASU 2016-02”) to forego assessing upon adoption: (1) whether any expired contracts are or contain leases; (2) the lease classification for any existing or expired leases and (3) any indirect costs that would have qualified for capitalization for any existing leases. We have lease agreements with lease and non-lease components, which are generally accounted for separately except for real estate leases, which we have elected to combine through a practical expedient under ASU 2016-02. Non-lease components for our leases typically consist of executory costs, and the practical expedient allows for executory costs to be recorded as lease payments. Additionally, for certain equipment leases, we apply a portfolio approach to effectively record right-of-use assets and liabilities.

Our operating leases mainly include office leases, and our finance leases included office and computer equipment leases. As of December 31, 2021, we no longer have finance leases. Our finance leases in 2021 were not significant. Our operating leases have remaining lease terms up to 5 years, some of which include options to extend the leases for up to 5 years, which may include options to terminate the leases within 1 year. Operating costs associated with leased assets are as follows:


(In thousands)	Three Months Ended June 30,						Six Months Ended June 30,
	2022			2021			2022			2021
Operating lease cost (1)	$	1,525		$	1,893		$	3,215		$	3,824
Less: Sublease income		(65	)		(74	)		(98	)		(157	)
Total operating lease costs	$	1,460		$	1,819		$	3,117		$	3,667

(1) Operating lease costs are recognized on a straight-line basis and are included in Selling, general and administrative expenses within the consolidated statements of operations.

Supplemental cash flow information for operating leases is as follows:


(In thousands)	Six Months Ended June 30,
	2022		2021
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$	3,562	$	3,585
Right-of-use assets obtained in exchange for operating lease obligations	$	273	$	0

The balance sheet location and balances for operating leases are as follows:


(In thousands, except lease term and discount rate)	June 30, 2022			December 31, 2021
Right-of-use assets - operating leases	$	15,904		$	18,324
Current operating lease liabilities	$	6,095		$	6,133
Long-term operating lease liabilities	$	13,873		$	16,754
Weighted average remaining lease term (in years)		4			5
Weighted average discount rate		3.3	%		3.4	%

The future maturities of our leasing arrangements including lease and non-lease components are shown in the below table. The maturities are calculated using foreign currency exchange rates in effect as of June 30, 2022.


	June 30, 2022
(In thousands)	Operating Leases
Remainder of 2022	$	3,318
2023		6,421
2024		3,706
2025		3,453
2026		2,835
Thereafter		1,581
Total lease liabilities		21,314
Less: Amount representing interest		(1,346	)
Less: Short-term lease liabilities		(6,095	)
Total Long-term lease liabilities	$	13,873

Business Combinations and Divestitures

6 Months Ended

Jun. 30, 2022

Business Combinations [Abstract]

Business Combinations and Divestitures

5. Business Combinations and Divestitures

Acquisitions

On March 25, 2022, we acquired Babel Health which engages in the business of designing, developing, selling and operating encounter data submission and reconciliation solutions. The base purchase price was $24.0 million, subject to adjustment for cash and net working capital balances, resulting in $24.5 million in cash paid ($24.0 million in net cash after accounting for the existing cash balance). The allocation of the purchase price is preliminary and subject to change. Accordingly, adjustments may be made to the values of assets and liabilities assumed as the valuation is finalized and additional information is obtained about the facts and circumstances that existed at the acquisition date. We expect to finalize the valuation and complete the purchase consideration allocation within the allowable measurement period. The management platform will provide managed health care plans with a tailored solution for the risk adjustment claims submission process. The business is included in our Veradigm reportable segment.

The preliminary purchase price allocation of the fair value of the consideration transferred as of the acquisition date of March 25, 2022 is shown in the table below. The goodwill is expected to be deductible for tax purposes.


	(In thousands)
Cash and cash equivalents	$	472
Accounts receivable, net		394
Prepaid expenses and other current assets		206
Fixed assets		48
Intangible assets		7,280
Goodwill		17,542
Accounts payable and accrued expenses		(752	)
Deferred revenue		(675	)
Other liabilities		(5	)
Net assets acquired	$	24,510

The following table summarizes the estimated fair values of the identifiable intangible assets and their estimated useful lives:


	Useful Life	Fair Value
Description	(In years)	(In thousands)
Customer Relationships	21	$	4,640
Technology	7		2,600
Tradenames	1		40
		$	7,280

We incurred $0.2 million of acquisition costs during the three and six months ended June 30, 2022, which are included in Selling, general and administrative expenses in our consolidated statement of operations. The results of operations of Babel Health were not material to our consolidated results of operations for the three and six months ended June 30, 2022.

Divestitures

On May 2, 2022, we completed the sale of our Hospitals and Large Physician Practices business, including the Sunrise and TouchWorks solutions (the “Hospitals and Large Physician Practices Business”) to Altera Digital Health Inc. (formerly known as Harris Dawn Holdings Inc.), a Delaware corporation (“Altera”), a wholly-owned subsidiary of Constellation Software Inc., an Ontario corporation, pursuant to a purchase agreement (the “Altera Purchase Agreement”) by which Altera purchased substantially all of the assets of the Hospitals and Large Physician Practices Business. The total consideration for the Hospitals and Large Physician Practices Business was $670.0 million in cash paid at closing, with up to an additional $30.0 million of contingent consideration based on the Hospitals and Large Physician Practices Business’s revenue through calendar year 2023. Certain assets relating to the Hospitals and Large Physician Practices Business were excluded from the transaction and retained by the Company, as described in the Altera Purchase Agreement. In addition, Altera assumed certain liabilities related to the Hospitals and Large Physician Practices Business under the terms of the Altera Purchase Agreement. We realized a pre-tax gain upon the sale of $2.8 million, which is included in the Gain on sale of discontinued operations line in our consolidated statements of operations for the three and six months ended June 30, 2022. The divestiture is being treated as a discontinued operation as of June 30, 2022. Refer to Note 15, “Discontinued Operations” for additional information regarding the historical assets, liabilities and results of operations of the Hospitals and Large Physician Practices Business.

On August 23, 2021, we completed the sale of substantially all of the assets of our 2bPrecise business to a third party for a non-controlling interest in the combined entity. We realized a pre-tax gain upon the sale of $8.4 million, which was included in the Gain on sale of businesses, net line in our consolidated statements of operations for the year ended December 31, 2021. The historical 2bPrecise business is presented in our “Unallocated Amounts” category.

On December 31, 2020, we completed the sale of substantially all of the assets of our CarePort business to a subsidiary of WellSky Corp., a Delaware corporation (“WellSky”), pursuant to a purchase agreement (the “CarePort Purchase Agreement”). The total consideration for CarePort was $1.35 billion, which was subject to certain adjustments for liabilities assumed by WellSky and net working capital as described in the CarePort Purchase Agreement. We realized a pre-tax gain upon the sale of $933.9 million, which was included in the Gain on sale of discontinued operations line in our consolidated statements of operations for the year ended December 31, 2020. For the year ended December 31, 2021, we recorded a $0.6 million gain that primarily related to net working capital adjustments in the Gain on sale of discontinued operations line in our consolidated statements of operations. The divestiture was treated as a discontinued operation as of December 31, 2020. Refer to Note 15, “Discontinued Operations” for additional information. On December 31, 2020, we repaid $161.0 million of the Term Loan (as defined below) as a result of the sale, which was a mandatory prepayment in accordance with the Second Amended Credit Agreement (as defined below).

On October 15, 2020, we completed the sale of substantially all of the assets of our EPSiTM business (“EPSi”) to Strata Decision Technology LLC, an Illinois limited liability company (“Strata”), and Roper Technologies, Inc., a Delaware corporation, pursuant to a purchase agreement (the “EPSi Purchase Agreement”). The total consideration for EPSi was $365.0 million, which was subject to certain adjustments for liabilities assumed by Strata and net working capital as described in the EPSi Purchase Agreement. We realized a pre-tax gain upon the sale of $222.6 million, which was included in the Gain on sale of discontinued operations line in our consolidated statements of operations for the year ended December 31, 2020. The divestiture was treated as a discontinued operation as of December 31, 2020. Refer to Note 15, “Discontinued Operations” for additional information. On October 29, 2020, we repaid $19.0 million of the Term Loan (as defined below) as a result of the sale, which was a mandatory prepayment in accordance with the Second Amended Credit Agreement (as defined below).

Fair Value Measurements and Long-term Investments

6 Months Ended

Jun. 30, 2022

Fair Value Disclosures [Abstract]

Fair Value Measurements and Long-term Investments

6. Fair Value Measurements and Long-term Investments

Fair value measurements are based upon observable and unobservable inputs.

Level 1: Inputs are unadjusted quoted prices in active markets for identical assets or liabilities at the measurement date.

Level 2: Quoted prices for similar instruments in active markets with inputs that are observable, either directly or indirectly. Our Level 2 derivative financial instruments include foreign currency forward contracts valued based upon observable values of spot and forward foreign currency exchange rates.

Level 3: Unobservable inputs are significant to the fair value of the asset or liability, and include situations where there is little, if any, market activity for the asset or liability. Our Level 3 instrument reflects the fair value of contingent consideration related to a completed acquisition. The fair value is based on a discounted cash flow analysis reflecting the likelihood of achieving specified performance measures or events and captures the contractual nature of the contingencies, commercial risk or time value of money.

The following table summarizes our financial assets and liabilities measured at fair value on a recurring basis as of the respective balance sheet dates:


	Balance Sheet	June 30, 2022								December 31, 2021
(In thousands)	Classifications	Level 1		Level 2		Level 3		Total		Level 1		Level 2		Level 3		Total
Foreign exchange derivative assets	Prepaid expenses and other current assets	$	0	$	0	$	0	$	0	$	0	$	352	$	0	$	352
Total assets		$	0	$	0	$	0	$	0	$	0	$	352	$	0	$	352

Foreign exchange derivative assets	Accrued expenses	$	0	$	54	$	0	$	54	$	0	$	0	$	0	$	0
Contingent consideration - current	Accrued expenses		0		0		0		0		0		0		19		19
Total liabilities		$	0	$	54	$	0	$	54	$	0	$	0	$	19	$	19

The changes in our Level 3 liability measured at fair value on a recurring basis at June 30, 2022 is summarized as follows:


(In thousands)	Contingent Consideration
Balance at December 31, 2021	$	19
Payments		(19	)
Balance at June 30, 2022	$	0

Long-term Investments

The following table summarizes our long-term equity investments which are included in Other assets in the accompanying consolidated balance sheets:


	Number of Investees		Original		Carrying Value at
(In thousands, except for number of investees)	at June 30, 2022		Cost		June 30, 2022		December 31, 2021
Equity method investments (1)		4	$	7,099	$	11,579	$	12,260
Cost with adjustments		7		47,114		49,109		49,293
Total long-term equity investments		11	$	54,213	$	60,688	$	61,553

(1) Allscripts share of the earnings of our equity method investees is reported based on a one quarter lag.

During the three and six months ended June 30, 2021, one of our third-party cost method investments converted its notes and we received 475 thousand shares in such third party as a result of the conversion. We also revalued our existing investment based on the note conversion share price. The note conversion and the revaluation of the existing investment resulted in a $9.7 million gain, which is included in the Other income, net line in our consolidated statements of operations for the three and six months ended June 30, 2021.

As of June 30, 2022, it is not practicable to estimate the fair value of our non-marketable cost and equity method investments, primarily because of their illiquidity and restricted marketability. The factors we considered in trying to determine fair value include, but are not limited to, available financial information, the issuer’s ability to meet its current obligations, the issuer’s subsequent or planned raises of capital and observable price changes in orderly transactions.

Impairment of Long-term Investments

Each quarter, management performs an assessment of each of our investments on an individual basis to determine if there have been any declines in fair value. Based on our assessment, we determined no impairment charges were necessary for the six months ended June 30, 2022.

Long-term Financial Liabilities

Our long-term financial liabilities include amounts outstanding under our Senior Secured Credit Facility (as described in Note 10, “Debt”), with carrying values that approximate fair value since the interest rates approximate current market rates. Refer to Note 10, “Debt,” for further information regarding our long-term financial liabilities.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Stockholders' Equity

6 Months Ended

Jun. 30, 2022

Equity [Abstract]

Stockholders' Equity

7. Stockholders' Equity

Stock-based Compensation Expense

Stock-based compensation expense recognized during the three and six months ended June 30, 2022 and 2021 is included in our consolidated statements of operations as shown in the below table. Stock-based compensation expense includes both non-cash expense related to grants of stock-based awards as well as cash expense related to the employee discount applied to purchases of our common stock under our employee stock purchase plan. No stock-based compensation costs were capitalized during the three and six months ended June 30, 2022 and 2021.


	Three Months Ended June 30,				Six Months Ended June 30,
(In thousands)	2022		2021		2022		2021
Cost of revenue:
Provider	$	221	$	220	$	538	$	496
Payer & Life Sciences		37		49		25		106
Total cost of revenue		258		269		563		602
Selling, general and administrative expenses		8,309		2,335		13,798		4,888
Research and development		596		938		1,726		2,006
Total stock-based compensation expense	$	9,163	$	3,542	$	16,087	$	7,496

Allscripts Long-Term Incentive Plan

We measure stock-based compensation expense at the grant date based on the fair value of the award. We recognize the expense for service-based share awards over the requisite service period on a straight-line basis, net of estimated forfeitures. We recognize the expense for performance-based and market-based share awards over the vesting period under the accelerated attribution method, net of estimated forfeitures. In addition, we recognize stock-based compensation cost for awards with performance conditions if and when we conclude that it is probable that the performance conditions will be achieved.

The fair value of service-based and performance-based restricted stock units is measured at the underlying closing share price of our common stock on the date of grant. The fair value of market-based restricted stock units is measured using the Monte Carlo pricing model. No stock options were granted during the six months ended June 30, 2022 and 2021.

We granted stock-based awards as follows:


	Three Months Ended June 30, 2022				Six Months Ended June 30, 2022
			Weighted-Average				Weighted-Average
			Grant Date				Grant Date
(In thousands, except per share amounts)	Shares		Fair Value		Shares		Fair Value
Service-based restricted stock units		1,221	$	18.41		1,246	$	18.44
Performance-based restricted stock units with a service condition		243	$	18.56		243	$	18.56
Market-based restricted stock units with a service condition		258	$	21.90		258	$	21.90
		1,722	$	18.95		1,747	$	18.97

During the six months ended June 30, 2022 and the year ended December 31, 2021, 2.5 million and 2.2 million shares of common stock, respectively, were issued in connection with the release of restrictions on stock awards.

Net Share-settlements

Upon vesting, restricted stock units are generally net share-settled to cover the required withholding tax, and the remaining amount is converted into an equivalent number of shares of common stock. The majority of restricted stock units and awards that vested during the six months ended June 30, 2022 and 2021 were net-share settled such that we withheld shares with fair value equivalent to the employees’ minimum statutory obligation for the applicable income and other employment taxes and remitted the cash to the appropriate taxing authorities. Total payments for the employees' minimum statutory tax obligations to the taxing authorities are reflected as a financing activity within the accompanying consolidated statements of cash flows. The total shares withheld for the six months ended June 30, 2022 and 2021 were 1.3 million and 895 thousand, respectively, and were based on the value of the restricted stock units on their vesting date as determined by our closing stock price. These net-share settlements had the effect of share repurchases by us as they reduced the number of shares that would have otherwise been issued as a result of the vesting.

Stock Repurchases

On November 18, 2020, we announced that our Board of Directors approved a stock purchase program (the “2020 Program”) under which we may repurchase up to $300 million of our common stock through December 31, 2021. The 2020 Program replaced a previous program that was fully utilized. During the three and six months ended June 30, 2021, we repurchased 5.6 million shares of our common stock under the 2020 Program for a total of $101.5 million, net of commissions. This was inclusive of the 1.6 million shares we received at final settlement of the accelerated share repurchase program we entered into on November 30, 2020. Please refer to Part II, Item 8 of our Form 10-K for further details on the accelerated share repurchase program.

On May 26, 2021, we announced that our Board approved a stock purchase program (the “2021 Program”) under which we may repurchase up to $350 million of our common stock. The 2021 Program replaced the 2020 Program that was fully utilized and did not have a termination date. During the three months ended June 30, 2021, we repurchased 11.5 million shares of our common stock under the 2021 Program for a total of $202.9 million, net of commissions. This was inclusive of the 9.1 million shares we received at initial settlement of the accelerated share repurchase program we entered into on June 14, 2021. Please refer to Part II, Item 8 of our Form 10-K for further details on the accelerated share repurchase program.

On January 24, 2022, we announced that our Board of Directors approved a stock purchase program (the “2022 Program”) under which we may repurchase up to $250 million of our common stock, with no termination date. The 2022 Program replaced the 2021 Program that was fully utilized. During the three months ended June 30, 2022, we repurchased 5.5 million shares of our common stock under the 2022 Program for a total of $93.7 million, net of commissions. During the six months ended June 30, 2022, we repurchased 7.8 million shares of our common stock under the 2022 Program for a total of $143.4 million, net of commissions.

The approximate dollar value of shares of our common stock that may yet be purchased under the 2022 Program was $106.8 million as of June 30, 2022. Any future stock repurchase transactions may be made through open market transactions, block trades, privately negotiated transactions (including accelerated share repurchase transactions) or other means, subject to market conditions. Any repurchase activity will depend on many factors such as our working capital needs, cash requirements for investments, debt repayment obligations, economic and market conditions at the time, including the price of our common stock, and other factors that we consider relevant. Our stock repurchase program may be accelerated, suspended, delayed or discontinued at any time.

Earnings (Loss) Per Share

6 Months Ended

Jun. 30, 2022

Earnings Per Share [Abstract]

Earnings (Loss) Per Share

8. Earnings (Loss) Per Share

Basic earnings (loss) per share is computed by dividing net income (loss) by the weighted-average shares of common stock outstanding. For purposes of calculating diluted earnings (loss) per share, the numerator includes net income (loss) and any interest expense related to the 0.875% Convertible Senior Notes, net of tax, and the denominator includes both the weighted-average shares of common stock outstanding and dilutive common stock equivalents. Dilutive common stock equivalents consist of restricted stock unit awards and warrants calculated under the treasury stock method, as well as convertible notes calculated under the if-converted method.

The calculations of earnings (loss) per share are as follows:


	Three Months Ended June 30,						Six Months Ended June 30,
(In thousands, except per share amounts)	2022			2021			2022			2021
Basic earnings (loss) per Common Share:
Income from continuing operations, net of tax	$	3,262		$	26,143		$	21,733		$	30,443
(Loss) income from discontinued operations, net of tax		(67,288	)		(4,217	)		(62,902	)		540
Net (loss) income	$	(64,026	)	$	21,926		$	(41,169	)	$	30,983

Weighted-average common shares outstanding		114,251			136,647			115,052			138,409

Basic earnings from continuing operations per Common Share	$	0.03		$	0.19		$	0.19		$	0.22
Basic (loss) earnings from discontinued operations per Common Share		(0.59	)		(0.03	)		(0.55	)		0.00
Net (loss) earnings per Common Share	$	(0.56	)	$	0.16		$	(0.36	)	$	0.22

Diluted earnings (loss) per Common Share:
Income from continuing operations, net of tax	$	3,262		$	26,143		$	21,733		$	30,443
Effect of assumed conversions:
Plus: Interest expense, net of tax, associated with 0.875% Convertible Senior Notes		507			0			1,013			0
Income from continuing operations, net of tax after the effect of assumed conversions	$	3,769		$	26,143		$	22,746		$	30,443

(Loss) income from discontinued operations, net of tax	$	(67,288	)	$	(4,217	)	$	(62,902	)	$	540

Weighted-average common shares outstanding		114,251			136,647			115,052			138,409
Plus: Dilutive effect of restricted stock unit awards, convertible notes and warrants		4,452			8,624			21,670			8,839
Weighted-average common shares outstanding assuming dilution		118,703			145,271			136,722			147,248

Diluted earnings from continuing operations per Common Share	$	0.03		$	0.18		$	0.17		$	0.21
Diluted (loss) earnings from discontinued operations per Common Share		(0.57	)		(0.03	)		(0.46	)		0.00
Net (loss) earnings per Common Share	$	(0.54	)	$	0.15		$	(0.29	)	$	0.21

The following restricted stock unit awards, convertible notes and warrants are not included in the computation of diluted earnings per share as the effect of including such restricted stock unit awards, convertible notes and warrants in the computation would be anti-dilutive:


	Three Months Ended June 30,				Six Months Ended June 30,
(In thousands)	2022		2021		2022		2021
Shares subject to anti-dilutive restricted stock unit awards, convertible notes and warrants excluded from calculation		15,814		1,502		92		1,501

Goodwill and Intangible Assets

6 Months Ended

Jun. 30, 2022

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill and Intangible Assets

9. Goodwill and Intangible Assets

Goodwill and intangible assets consist of the following:


	June 30, 2022							December 31, 2021
	Gross							Gross
	Carrying		Accumulated			Intangible		Carrying		Accumulated			Intangible
(In thousands)	Amount		Amortization			Assets, Net		Amount		Amortization			Assets, Net
Intangibles subject to amortization:
Proprietary technology	$	252,083	$	(230,757	)	$	21,326	$	249,483	$	(227,408	)	$	22,075
Customer contracts and relationships		402,125		(326,241	)		75,884		397,445		(321,830	)		75,615
Total	$	654,208	$	(556,998	)	$	97,210	$	646,928	$	(549,238	)	$	97,690

Intangibles not subject to amortization:
Registered trademarks						$	52,000						$	52,000
Goodwill							524,149							506,607
Total						$	576,149						$	558,607

Changes in the carrying amounts of goodwill by reportable segment for the six months ended June 30, 2022 were as follows:


(In thousands)	Veradigm		Unallocated		Total
Balance as of December 31, 2021		467,630		38,977		506,607
Additions		17,542		0		17,542
Balance as of June 30, 2022	$	485,172	$	38,977	$	524,149

There were no accumulated impairment losses associated with goodwill as of June 30, 2022 and December 31, 2021.

Debt

6 Months Ended

Jun. 30, 2022

Debt Disclosure [Abstract]

Debt

10. Debt

Debt outstanding, excluding lease obligations, consists of the following:


	June 30, 2022							December 31, 2021
(In thousands)	Principal Balance		Unamortized Discount and Debt Issuance Costs		Net Carrying Amount			Principal Balance		Unamortized Discount and Debt Issuance Costs			Net Carrying Amount
0.875% Convertible Senior Notes (1)	$	207,911	$	4,104	$	203,807		$	167,853	$	(9,057	)	$	176,910
Senior Secured Credit Facility		0		3,912		(3,912	)		175,000		1,848			173,152
Total debt	$	207,911	$	8,016	$	199,895		$	342,853	$	(7,209	)	$	350,062

(1) As of June 30, 2022, the principal balance is recognized in debt. As of December 31, 2021, the principal balance is $207,911 thousand; $167,853 thousand is recognized in debt and $40,058 thousand is recognized in additional paid-in capital.

Interest expense consists of the following:


	Three Months Ended June 30,				Six Months Ended June 30,
(In thousands)	2022		2021		2022		2021
Interest expense	$	1,084	$	1,079	$	2,590	$	2,367
Amortization of discounts and debt issuance costs		803		1,870		1,433		3,725
Total interest expense	$	1,887	$	2,949	$	4,023	$	6,092

Interest expense related to the 0.875% Convertible Senior Notes included in the table above consists of the following:


	Three Months Ended June 30,				Six Months Ended June 30,
(In thousands)	2022		2021		2022		2021
Coupon interest	$	455	$	455	$	910	$	910
Amortization of discounts and debt issuance costs		228		1,474		456		2,933
Total interest expense related to the 0.875% Convertible Senior Notes	$	683	$	1,929	$	1,366	$	3,843

Allscripts Senior Secured Credit Facility

On April 29, 2022, Allscripts and Allscripts Healthcare LLC entered into a Third Amended and Restated Credit Agreement (the “Third Amended Credit Agreement”), with JPMorgan Chase Bank, N.A., as administrative agent and other lenders party thereto, amending and restating the Second Amended Credit Agreement. The Third Amended Credit Agreement provides for a $700.0 million senior secured revolving facility (the “New Revolving Facility”). A total of up to $50.0 million of the New Revolving Facility is available for the issuance of letters of credit, up to $25.0 million of the New Revolving Facility is available for swingline loans, and up to $100.0 million of the New Revolving Facility can be borrowed under certain foreign currencies. Proceeds from the borrowings under the Third Amended Credit Agreement were used for the refinancing of loans under the Second Amended Credit Agreement.

As of June 30, 2022, $0.8 million in letters of credit were outstanding under the Third Amended Credit Agreement. No amounts under the New Revolving Facility were outstanding under the Third Amended Credit Agreement as of June 30, 2022. We were in compliance with all covenants under the Third Amended Credit Agreement as of June 30, 2022.

As of June 30, 2022, we had $699.2 million available borrowing capacity, net of any outstanding letters of credit, under the New Revolving Facility. There can be no assurance that we will be able to draw on the full available balance of the New Revolving Facility if the financial institutions that have extended such credit commitments become unwilling or unable to fund such borrowings or if we are unable to maintain compliance with applicable covenants.

0.875% Convertible Senior Notes

The issuance in December 2019 of the combined $218.0 million aggregate principal amount of the 0.875% Convertible Senior Notes resulted in $0.7 million in debt issuance costs, which were paid in January 2020. We have separately recorded liability and equity components of the 0.875% Convertible Senior Notes, including any discounts and issuance costs, by allocating the proceeds from the issuance between the liability component and the embedded conversion option, or equity component. This allocation was completed by first estimating an interest rate at the time of issuance for similar notes that do not include an embedded conversion option. The semi-annual interest rate of 1.95% was used to compute the initial fair value of the liability component, which totaled $177.9 million at the time of issuance. The excess of the initial proceeds received from the 0.875% Convertible Senior Notes and the $177.9 million liability component was allocated to the equity component, which totaled $40.1 million at the time of issuance before deducting any paid capped call fees. The equity component of $40.1 million, the $17.2 million in paid capped call fees and an allocation of $1.1 million in combined discounts and issuance costs were recorded in Additional paid-in capital within the consolidated balance sheets in December 2019. These were recorded as a discount and are to be accreted into interest expense through January 1, 2027 using the interest method.

In June 2020, we paid $7.7 million to repurchase $10.1 million of the aggregate principal amount of the 0.875% Convertible Senior Notes, which resulted in a $0.5 million gain. In connection with the repurchase, the capped call transaction was partially terminated, and we received $0.3 million, which resulted in a recognition of $0.8 million in equity to offset the capped call fees and a $0.5 million loss.

On January 1, 2022, we adopted ASU 2020-06 using the modified retrospective transition method. The guidance simplifies the accounting for convertible instruments by removing major separation models required under GAAP. The guidance also removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exceptions. As a result of the adoption of ASU 2020-06, the liability and equity components of the 0.875% Convertible Senior Notes are to be presented as a single liability as of January 1, 2022. Therefore, as of January 1, 2022, we decreased Additional paid-in capital by $38.9 million, which represented the $40.1 million equity component, offset by the $1.1 million in combined discounts and issuance costs. We increased Retained earnings by $12.5 million to reverse the accretion of interest expense related to the equity component that was recorded from December 2019 through December 2021. We also increased Long-term debt by $26.4 million, which represents the difference between the reduction to Additional paid-in capital and the increase in Retained earnings. The capped call fees remain in Additional paid-in capital within our consolidated balance sheet.

The 0.875% Convertible Senior Notes became convertible at the option of the holders during the first quarter of 2022. However, as of June 30, 2022, none of the 0.875% Convertible Senior Notes have been converted. The remaining principal amount of the 0.875% Convertible Senior Notes at June 30, 2022 totaled $207.9 million. The carrying value of the capped call fees at June 30, 2022 was $16.4 million.

Future Debt Payments

The following table summarizes future debt principal payment obligations as of June 30, 2022:



(In thousands)	Total		Remainder of 2022		2023		2024		2025		2026		Thereafter
0.875% Convertible Senior Notes (1)	$	207,911	$	0	$	0	$	0	$	0	$	0	$	207,911
Total debt	$	207,911	$	0	$	0	$	0	$	0	$	0	$	207,911

(1) Amount represents the face value of the 0.875% Convertible Senior Notes.

Income Taxes

6 Months Ended

Jun. 30, 2022

Income Tax Disclosure [Abstract]

Income Taxes

11. Income Taxes

We account for income taxes under FASB Accounting Standards Codification 740, “Income Taxes” (“ASC 740”). We calculate the quarterly tax provision consistent with the guidance provided by ASC 740, whereby we forecast the estimated annual effective tax rate and then apply that rate to the year-to-date pre-tax book (loss) income. The effective tax rate may be subject to fluctuations during the year as new information is obtained, which may affect the assumptions used to estimate the annual effective rate, including factors such as the valuation allowances against deferred tax assets, the recognition or de-recognition of tax benefits related to uncertain tax positions, or changes in or the interpretation of tax laws in jurisdictions where the Company conducts business. There is no tax benefit recognized on certain of the net operating losses incurred due to insufficient evidence supporting the Company’s ability to use these losses in the future. The effective tax rates were as follows:


	Three Months Ended June 30,						Six Months Ended June 30,
(In thousands, except effective tax rate)	2022			2021			2022			2021
(Loss) income from continuing operations before income taxes	$	(5,317	)	$	30,311		$	(1,267	)	$	35,717
Income tax benefit (provision)	$	8,579		$	(4,168	)	$	23,000		$	(5,274	)
Effective tax rate		161.4	%		13.8	%	NM				14.8	%

NM - We define “NM” as not meaningful for percentages greater than 200%.

Our provision for income taxes differs from the tax computed at the U.S. federal statutory income tax rate primarily due to permanent differences, income attributable to foreign jurisdictions taxed at different rates, state taxes, tax credits and certain discrete items including a windfall benefit of $11.2 million for the six months ended June 30, 2022 and a windfall benefit of $4.6 million for the six months ended June 30, 2021. Our effective tax rates for the three and six months ended June 30, 2022, compared with the prior year comparable period, differ primarily due to the release of valuation allowance of $11.2 million in both the three and six months ended June 30, 2022. In addition, the permanent items, credits and the impact of foreign earnings had more impact on the pre-tax income of $4.1 million and pre-tax loss of $1.3 million in the three and six months ended June 30, 2022, compared to the impact of these items on a pre-tax income of $5.4 million and $35.7 million for the three and six months ended June 30, 2021.

In evaluating our ability to recover our deferred tax assets within the jurisdictions from which they arise, we consider all available evidence, including scheduled reversals of deferred tax liabilities, tax-planning strategies, and results of recent operations. In evaluating the objective evidence that historical results provide, we consider three years of cumulative operating income (loss). During the six months ended June 30, 2022, we released valuation allowances of $11.2 million related to U.S. deferred tax assets.

Our unrecognized income tax benefits were $30.5 million and $30.3 million as of June 30, 2022 and December 31, 2021, respectively. If any portion of our unrecognized tax benefits is recognized, it could impact our effective tax rate. The tax reserves are reviewed periodically and adjusted considering changing facts and circumstances, such as progress of tax audits, lapse of applicable statutes of limitations and changes in tax law.

The sale of the Hospitals and Large Physician Practices Business included the majority of our foreign subsidiaries. In the quarter ended March 31, 2022, the assets and liabilities of these foreign subsidiaries were classified as held for sale on our consolidated balance sheet. As such, the company no longer considered the undistributed earnings of these foreign subsidiaries to be indefinitely invested. Therefore, in the three months ended March 31, 2022, we recorded a deferred tax asset of $7.0 million. The tax benefit of recording this deferred tax asset was included in discontinued operations. With the completed sale of the Hospitals and Large Physician Practices Business, this deferred tax asset was written off in the quarter ended June 30, 2022.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 21
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-URI https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 17
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.5.Q1)
-URI https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 14
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 270
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-URI https://asc.fasb.org/topic&trid=2144680

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

+ Details

Derivative Financial Instruments

6 Months Ended

Jun. 30, 2022

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Derivative Financial Instruments

12. Derivative Financial Instruments

The following tables provide information about the fair values of our derivative financial instruments as of the respective balance sheet dates:

June 30, 2022

Asset Derivatives

Liability Derivatives

(In thousands)

Balance Sheet Location

Fair Value

Balance Sheet Location

Fair Value

Derivatives qualifying as cash flow hedges:

Foreign exchange contracts

Prepaid expenses and other current assets

0

Accrued expenses

54

Total derivatives

0

54

December 31, 2021

Asset Derivatives

Liability Derivatives

(In thousands)

Balance Sheet Location

Fair Value

Balance Sheet Location

Fair Value

Derivatives qualifying as cash flow hedges:

Foreign exchange contracts

Prepaid expenses and other current assets

352

Accrued expenses

0

Total derivatives

352

-

Foreign Exchange Contracts

We have entered into non-deliverable forward foreign currency exchange contracts with reputable banking counterparties to hedge a portion of our forecasted future Indian Rupee-denominated (“INR”) expenses against foreign currency fluctuations between the United States dollar and the INR. These forward contracts cover a percentage of forecasted monthly INR expenses over time. As of June 30, 2022, there were six forward contracts outstanding that when entered into were staggered to mature monthly starting in July 2022 and ending in December 2022. In the future, we may enter into additional forward contracts to increase the amount of hedged monthly INR expenses or initiate hedges for monthly periods beyond December 2022. As of June 30, 2022, the notional amount for each of the outstanding forward contracts was 50 million INR, or the equivalent of $0.6 million, based on the exchange rate between the United States dollar and the INR in effect as of June 30, 2022. These amounts also approximate the forecasted future INR expenses we target to hedge in any one month in the future. As of June 30, 2022, we estimate that $0.1 million of net unrealized derivative losses included in accumulated other comprehensive income (loss) (“AOCI”) will be reclassified into income within the next 12 months.

The following tables show the impact of derivative instruments designated as cash flow hedges on the consolidated statements of operations and the consolidated statements of comprehensive income (loss):


	Amount of Gain (Loss) Recognized in OCI							Amount of Gain (Loss) Reclassified from AOCI into Income
(In thousands)	Three Months Ended June 30, 2022			Six Months Ended June 30, 2022			Location of Gain (Loss) Reclassified from AOCI into Income	Three Months Ended June 30, 2022			Six Months Ended June 30, 2022
Foreign exchange contracts	$	(155	)	$	(303	)	Cost of Revenue	$	(1	)	$	36
							Selling, general and administrative expenses		0			24
							Research and development	$	(1	)	$	42


	Amount of Gain (Loss) Recognized in OCI						Amount of Gain (Loss) Reclassified from AOCI into Income
(In thousands)	Three Months Ended June 30, 2021			Six Months Ended June 30, 2021		Location of Gain (Loss) Reclassified from AOCI into Income	Three Months Ended June 30, 2021		Six Months Ended June 30, 2021
Foreign exchange contracts	$	(54	)	$	121	Cost of Revenue	$	290	$	611
						Selling, general and administrative expenses		167		351
						Research and development	$	317	$	668

Accumulated Other Comprehensive Loss

6 Months Ended

Jun. 30, 2022

Equity [Abstract]

Accumulated Other Comprehensive Loss

13. Accumulated Other Comprehensive Loss

Accumulated Other Comprehensive Loss

Changes in the balances of each component included in AOCI are presented in the tables below. All amounts are net of tax.


(In thousands)	Foreign Currency Translation Adjustments			Unrealized Net Gains (Losses) on Foreign Exchange Contracts			Total
Balance as of December 31, 2021 (1)	$	(3,026	)	$	261		$	(2,765	)
Other comprehensive (loss) income before reclassifications		(867	)		(226	)		(1,093	)
Net losses (gains) reclassified from accumulated other comprehensive loss		0			(76	)		(76	)
Net other comprehensive income (loss)		(867	)		(302	)		(1,169	)
Balance as of June 30, 2022 (2)	$	(3,893	)	$	(41	)	$	(3,934	)

(1) Net of taxes of $91 thousand for unrealized net gains on foreign exchange contract derivatives.

(2) Net of taxes of $14 thousand for unrealized net losses on foreign exchange contract derivatives.


(In thousands)	Foreign Currency Translation Adjustments			Unrealized Net Gains (Losses) on Foreign Exchange Contracts			Total
Balance as of December 31, 2020 (1)	$	(2,957	)	$	1,119		$	(1,838	)
Other comprehensive income (loss) before reclassifications		520			90			610
Net (gains) losses reclassified from accumulated other comprehensive loss		0			(1,209	)		(1,209	)
Net other comprehensive income (loss)		520			(1,119	)		(599	)
Balance as of June 30, 2021	$	(2,437	)	$	0		$	(2,437	)

(1) Net of taxes of $390 thousand for unrealized net gains on foreign exchange contract derivatives.

Income Tax Effects Related to Components of Other Comprehensive Income (Loss)

The following tables reflect the tax effects allocated to each component of other comprehensive income (loss) (“OCI”):


	Three Months Ended June 30,
	2022									2021
(In thousands)	Before-Tax Amount			Tax Effect			Net Amount			Before-Tax Amount			Tax Effect		Net Amount
Foreign currency translation adjustments	$	(717	)	$	0		$	(717	)	$	421		$	0	$	421
Derivatives qualifying as cash flow hedges:
Foreign exchange contracts:
Net (losses) gains arising during the period		(155	)		39			(116	)		(54	)		14		(40	)
Net losses (gains) reclassified into income		2			(1	)		1			(774	)		200		(574	)
Net change in unrealized (losses) gains on foreign exchange contracts		(153	)		38			(115	)		(828	)		214		(614	)
Other comprehensive (loss) income	$	(870	)	$	38		$	(832	)	$	(407	)	$	214	$	(193	)


	Six Months Ended June 30,
	2022								2021
(In thousands)	Before-Tax Amount			Tax Effect		Net Amount			Before-Tax Amount			Tax Effect			Net Amount
Foreign currency translation adjustments	$	(867	)	$	0	$	(867	)	$	520		$	0		$	520
Derivatives qualifying as cash flow hedges:
Foreign exchange contracts:
Net (losses) gains arising during the period		(303	)		77		(226	)		121			(31	)		90
Net (gains) losses reclassified into income		(101	)		25		(76	)		(1,630	)		421			(1,209	)
Net change in unrealized (losses) gains on foreign exchange contracts		(404	)		102		(302	)		(1,509	)		390			(1,119	)
Other comprehensive (loss) income	$	(1,271	)	$	102	$	(1,169	)	$	(989	)	$	390		$	(599	)

Contingencies

6 Months Ended

Jun. 30, 2022

Commitments and Contingencies Disclosure [Abstract]

Contingencies

14. Contingencies

In addition to commitments and obligations in the ordinary course of business, we are currently subject to various legal proceedings and claims that have not been fully adjudicated. We intend to vigorously defend ourselves, as appropriate, in these matters.

No less than quarterly, we review the status of each significant matter and assess our potential financial exposure. We accrue a liability for an estimated loss if the potential loss from any legal proceeding or claim is considered probable and the amount can be reasonably estimated. Significant judgment is required in both the determination of probability and the determination as to whether the amount of an exposure is reasonably estimable, and accruals are based only on the information available to our management at the time the judgment is made.

The outcome of legal proceedings is inherently uncertain, and we may incur substantial defense costs and expenses defending any of these matters. In the opinion of our management, the ultimate disposition of pending legal proceedings or claims will not have a material adverse effect on our consolidated financial position, liquidity or results of operations. However, if one or more of these legal proceedings were resolved against or settled by us in a reporting period for amounts in excess of our management’s expectations, our consolidated financial statements for that and subsequent reporting periods could be materially adversely affected. Additionally, the resolution of a legal proceeding against us could prevent us from offering our products and services to current or prospective clients or cause us to incur increased compliance costs, either of which could further adversely affect our operating results.

The Enterprise Information Solutions business (the “EIS Business”) acquired from McKesson Corporation (“McKesson”) on October 2, 2017 is subject to a May 2017 civil investigative demand (“CID”) from the U.S. Attorney’s Office for the Eastern District of New York related to the Horizon Clinicals software. In August 2018, McKesson received an additional CID (together with the May 2017 CID, the “McKesson CIDs”), related to the Paragon software. The McKesson CIDs request documents and information related to the certification McKesson obtained in connection with the U.S. Department of Health and Human Services’ Electronic Health Record Incentive Program. McKesson has agreed, with respect to the McKesson CIDs, to indemnify Allscripts for amounts paid or payable to the government (or any private relator) involving any products or services marketed, sold or licensed by the EIS Business as of or prior to the closing of the acquisition. In October 2021, Allscripts received a CID seeking information about its acquisition of the EIS Business from McKesson and the Horizon Clinicals software. McKesson has agreed to assume defense of this CID. In May 2022, Allscripts completed the sale of the assets of its Hospital and Large Physician Practices Business to Altera. This divestiture included the sale of the Paragon software; however, the divestiture did not include the Horizon Clinicals software or liabilities arising from the McKesson CIDs.

Practice Fusion, acquired by Allscripts on February 13, 2018, received in March 2017 a request for documents and information from the U.S. Attorney’s Office for the District of Vermont pursuant to a CID. Between April 2018 and June 2019, Practice Fusion received from the U.S. Department of Justice (the “DOJ”) seven additional requests for documents and information through four additional CIDs and three Health Insurance Portability and Accountability Act (“HIPAA”) subpoenas. The document and information requests received by Practice Fusion related to both the certification Practice Fusion obtained in connection with the U.S. Department of Health and Human Services’ Electronic Health Record Incentive Program and Practice Fusion’s compliance with the Anti-Kickback Statute (“AKS”) and HIPAA as it relates to certain business practices engaged in by Practice Fusion. In March 2019, Practice Fusion received a grand jury subpoena in connection with a criminal investigation related to Practice Fusion’s compliance with the AKS. On August 6, 2019, Practice Fusion reached an agreement in principle with the DOJ to resolve all of the DOJ’s outstanding civil and criminal investigations, including the investigation by the U.S. Attorney’s Office for the District of Vermont, and we announced that on January 27, 2020, Practice Fusion entered into a deferred prosecution agreement (the “Deferred Prosecution Agreement”) and various civil settlement agreements, including with the Medicaid programs for each U.S. state, the District of Columbia and Puerto Rico (collectively, the “Settlement Agreements”) resolving the investigations conducted by the DOJ and the U.S. Attorney’s Office. The Settlement Agreements required Practice Fusion to, among other things, pay a criminal fine of $25.3 million, a forfeiture payment of $959,700 and a civil settlement of $118.6 million, which includes $5.2 million designated for the state Medicaid program expenditures, all of which, as of December 31, 2020, were paid in full. The Deferred Prosecution Agreement required Practice Fusion to retain an “Oversight Organization” to oversee the Practice Fusion’s implementation of certain compliance measures and ongoing compliance efforts. On August 17, 2021, Practice Fusion’s initial Oversight Organization resigned, and on August 25, 2021, Practice Fusion received a notice from the U.S. Attorney’s Office for the District of Vermont stating Practice Fusion was in breach of the Deferred Prosecution Agreement due to such resignation. On September 17, 2021, Practice Fusion engaged a new Oversight Organization. On March 18, 2022, Practice Fusion reached a settlement with the U.S. Attorney’s Office concerning this claim, pursuant to which Practice Fusion agreed to pay $200,000 to the United States and extend the Deferred Prosecution Agreement by 11 weeks; Practice Fusion did not admit liability for any breach of the Deferred Prosecution Agreement. The settlement of $200,000 was paid by Practice Fusion on April 5, 2022.

Discontinued Operations

6 Months Ended

Jun. 30, 2022

Discontinued Operations and Disposal Groups [Abstract]

Discontinued Operations

15. Discontinued Operations

Hospitals and Large Physician Practices Discontinued Operation

On May 2, 2022, we sold substantially all of the assets of the Hospitals and Large Physician Practices Business. The Hospitals and Large Physician Practices Business sale represented a strategic shift that had a major effect on our operations and financial results. As of June 30, 2022, we reported the Hospitals and Large Physician Practices Business as discontinued operations. Prior to the sale, the Hospitals and Large Physician Practices Business was part of the former Hospitals and Large Physician Practices reportable segment.

The following table summarizes the major classes of assets and liabilities of the Hospitals and Large Physician Practices Business as reported on the consolidated balance sheets as of June 30, 2022 and December 31, 2021:


(In thousands)	June 30, 2022		December 31, 2021
Carrying amounts of major classes of assets associated with Hospitals and Large Physician Practices included as part of discontinued operations:
Cash and cash equivalents	$	20,000	$	55,834
Restricted cash		0		861
Accounts receivable, net of allowance of $16,584 as of December 31, 2021		0		155,447
Contract assets, net of allowance of $492 as of December 31, 2021		0		61,382
Prepaid expenses and other current assets		0		58,431
Total current assets attributable to discontinued operations		20,000		331,955

Fixed assets, net		0		38,083
Software development costs, net		0		97,416
Intangible assets, net		0		86,240
Goodwill		0		467,871
Deferred taxes, net		0		6,607
Contract assets - long-term, net of allowance of $739 as of December 31, 2021		0		28,623
Right-of-use assets - operating leases		0		50,585
Other assets		0		17,731
Total long-term assets attributable to discontinued operations	$	0	$	793,156

Carrying amounts of major classes of liabilities associated with Hospitals and Large Physician Practices included as part of discontinued operations:

Accounts payable	$	30,372	$	11,555
Accrued expenses		0		38,007
Accrued compensation and benefits		0		61,167
Deferred revenue		0		205,152
Current operating lease liabilities		0		13,466
Total current liabilities attributable to discontinued operations		30,372		329,347

Deferred revenue long-term		0		2,568
Long-term operating lease liabilities		0		48,068
Other liabilities		0		270
Total long-term liabilities attributable to discontinued operations	$	0	$	50,906

The following table summarizes the major income and expense line items of the Hospitals and Large Physician Practices Business as reported in the consolidated statements of operations for the three and six months ended June 30, 2022 and 2021.


	Three Months Ended June 30,						Six Months Ended June 30,
(In thousands)	2022			2021			2022			2021
Major income and expense line items related to Hospitals and Large Physician Practices:
Revenue:
Provider	$	70,569		$	232,508		$	284,799		$	467,208
Total revenue		70,569			232,508			284,799			467,208
Cost of revenue:
Provider		45,806			149,175			189,498			296,747
Total cost of revenue		45,806			149,175			189,498			296,747
Gross profit		24,763			83,333			95,301			170,461
Selling, general and administrative expenses		19,782			50,966			68,531			100,511
Research and development		8,130			30,277			31,986			58,790
Asset impairment charges		0			5,072			0			5,072
Amortization of intangible assets		88			3,461			3,538			6,921
Loss from discontinued operations for Hospitals and Large Physician Practices		(3,237	)		(6,443	)		(8,754	)		(833	)
Other (loss) income, net		(484	)		229			12			468
Gain on sale of discontinued operations		2,765			0			2,765			0
Equity in net (loss) income of unconsolidated investments		(76	)		0			(76	)		0
Loss from discontinued operations for Hospitals and Large Physician Practices before income taxes		(1,032	)		(6,214	)		(6,053	)		(365	)
Income tax (provision) benefit		(66,256	)		1,976			(56,849	)		420
(Loss) income from discontinued operations, net of tax for Hospitals and Large Physician Practices	$	(67,288	)	$	(4,238	)	$	(62,902	)	$	55

EPSi and CarePort Discontinued Operations

During 2020, we implemented a strategic initiative to sell two of our businesses, EPSi and CarePort. Since both businesses were part of the same strategic initiative and were sold within the same period, the combined sale of EPSi and CarePort represented a strategic shift that had a major effect on our operations and financial results. As of December 31, 2020, these businesses were reported together as discontinued operations.

On October 15, 2020, we completed the sale of our EPSi business. Prior to the sale, EPSi was part of the “Unallocated Amounts” category as it did not meet the requirements to be a reportable segment nor the criteria to be aggregated into our two reportable segments at this time. On its own, the divestiture of the EPSi business did not represent a strategic shift that had a major effect on our operations and financial results. However, the combined sale of EPSi and CarePort represented a strategic shift that had a major effect on our operations and financial results. Therefore, EPSi was treated as a discontinued operation.

On December 31, 2020, we completed the sale of our CarePort business. Prior to the sale, CarePort was part of the former Data, Analytics and Care Coordination reportable segment. On its own, the divestiture of the CarePort business represented a strategic shift that had a major effect on our operations and financial results.

The following table summarizes the major income and expense line items of EPSi and CarePort as reported in the consolidated statements of operations for the three and six months ended June 30, 2021. The activity during the three and six months ended June 30, 2021 relates to certain adjustments made in connection with the sale of EPSi and CarePort, primarily relating to net working capital adjustments that impacted the gain on the sale of the discontinued operations.


	Three Months Ended			Six Months Ended
(In thousands)	June 30, 2021			June 30, 2021
Major income and expense line items related to EPSi and CarePort:
Revenue:
Provider	$	368		$	0
Total revenue		368			0
Cost of revenue:
Provider		316			(48	)
Total cost of revenue		316			(48	)
Gross profit		52			48
Selling, general and administrative expenses		9			74
Research and development		8			(32	)
Income from discontinued operations for EPSi and CarePort		35			6
Other income, net		1			1
Gain on sale of discontinued operations		0			647
Income from discontinued operations for EPSi and CarePort before income taxes		36			654
Income tax provision		(15	)		(169	)
Income from discontinued operations, net of tax for EPSi and CarePort	$	21		$	485

Business Segments

6 Months Ended

Jun. 30, 2022

Segment Reporting [Abstract]

Business Segments

16. Business Segments

Our two primary revenue streams are (i) provider revenue and (ii) payer and life sciences revenue. We primarily derive our provider revenues from sales of our proprietary software (either as a direct license sale or under a subscription delivery model), which also serves as the basis for our recurring service contracts for software support and maintenance and certain transaction-related services. In addition, we provide various other client services, including installation, and managed services, such as outsourcing, private cloud hosting and revenue cycle management. Payer and life sciences revenue primarily consists of sales of our integrated data systems solutions and related services to key healthcare stakeholders, including health plans and pharmaceutical companies, to help them improve the quality, efficiency and value of healthcare delivery.

As of January 1, 2022, we had three operating segments: (i) Hospitals and Large Physician Practices, (ii) Veradigm and (iii) Certain Products (as defined below). The Hospitals and Large Physician Practices and Veradigm operating segments were equivalent to the two reportable segments described below.

The Hospitals and Large Physician Practices segment derived its revenue from the sale of integrated clinical and financial management solutions, which primarily included EHR-related software, related installation, support and maintenance, outsourcing and private cloud hosting. The Veradigm segment derived its revenue from payer and life sciences solutions, which are mainly targeted at payers, life sciences companies and other key healthcare stakeholders. Additionally, revenue was derived from software applications for patient engagement and the sale of EHR software to single-specialty and small and mid-sized physician practices, including related clinical, financial, administrative and operational solutions. These solutions enabled clients to transition, analyze and coordinate care and improve the quality, efficiency and value of healthcare delivery across the entire care community. The “Unallocated Amounts” category consisted of the 2bPrecise business, certain products that were shifted from the previous Core Clinical and Financial Solutions reportable segment due to the organizational changes (“Certain Products”), transfer pricing revenues and certain corporate-related expenses. The amounts included in the “Unallocated Amounts” category for 2bPrecise and Certain Products did not meet the requirements to be reportable segments nor the criteria to be aggregated into the two reportable segments.

On March 2, 2022, we entered into a purchase agreement to sell substantially all of the assets of our Hospitals and Large Physician Practices Business. As of March 31, 2022, the assets and liabilities related to the purchase agreement were classified as held for sale on our consolidated balance sheet. We also classified the related assets and liabilities in discontinued operations, as the Hospitals and Large Physician Practices Business disposition represented a strategic shift that had a major effect on our operations and financial results. As a result of the transaction, we realigned our reporting structure. As of March 31, 2022, we had two operating segments: (i) Veradigm and (ii) Certain Products. The Veradigm operating segment was the equivalent to our one reportable segment. On May 2, 2022, we completed the sale of the Hospitals and Large Physician Practices Business. As of June 30, 2022, our two operating segments and one reportable segment remain unchanged from the first quarter of 2022. The prior period segment disclosures below have been revised to conform to the current period presentation.

Our chief operating decision maker uses segment revenues, gross profit and income (loss) from operations as measures of performance and to make decisions about the allocation of resources. We do not track our assets by segment.


	Three Months Ended June 30,						Six Months Ended June 30,
(In thousands)	2022			2021			2022			2021
Revenue:
Veradigm	$	144,637		$	133,449			280,915			259,819
Unallocated Amounts		6,261			7,757			12,655			15,039
Total revenue	$	150,898		$	141,206		$	293,570		$	274,858

Gross profit:
Veradigm	$	75,409		$	63,641			144,604			122,264
Unallocated Amounts		4,073			4,778			8,359			9,072
Total gross profit	$	79,482		$	68,419		$	152,963		$	131,336

Income (loss) from operations:
Veradigm	$	23,974		$	18,014			42,089			29,508
Unallocated Amounts		(29,330	)		(1,196	)		(40,873	)		(4,961	)
Total (loss) income from operations	$	(5,356	)	$	16,818		$	1,216		$	24,547

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (e)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 15
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-URI https://asc.fasb.org/topic&trid=2134510

+ Details

Supplemental Disclosures

6 Months Ended

Jun. 30, 2022

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Supplemental Disclosures

17. Supplemental Disclosures

Supplemental Consolidated Statements of Cash Flows Information

The majority of the restricted cash balance as of June 30, 2022 and 2021 represents lease deposits.


	June 30,
(In thousands)	2022		2021
Reconciliation of cash, cash equivalents and restricted cash:
Cash and cash equivalents	$	500,164	$	159,556
Restricted cash		1,307		1,307
Total cash, cash equivalents and restricted cash	$	501,471	$	160,863

	Six Months Ended June 30,
(In thousands)	2022		2021
Supplemental non-cash information:
Issuance of treasury stock to commercial partner	$	0	$	534

Basis of Presentation and Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation The consolidated financial statements include the accounts of Allscripts Healthcare Solutions, Inc. (“Allscripts”) and its wholly-owned subsidiaries and controlled affiliates. All significant intercompany balances and transactions have been eliminated. Each of the terms “we,” “us,” “our” or the “Company” as used herein refers collectively to Allscripts Healthcare Solutions, Inc. and its wholly-owned subsidiaries and controlled affiliates, unless otherwise stated.
Unaudited Interim Financial Information	Unaudited Interim Financial Information The unaudited interim consolidated financial statements as of and for the three and six months ended June 30, 2022 and 2021 have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (the “SEC”) for interim financial reporting. These interim consolidated financial statements are unaudited and, in the opinion of our management, include all adjustments, consisting of normal recurring adjustments and accruals, necessary to present fairly the consolidated financial statements for the periods presented in accordance with generally accepted accounting principles in the United States of America (“GAAP”). The consolidated results of operations for the three and six months ended June 30, 2022 are not necessarily indicative of the results to be expected for the full year ending December 31, 2022. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with GAAP have been condensed or omitted in accordance with the SEC's rules and regulations for interim reporting. The Company believes that the disclosures made are adequate to make these unaudited interim consolidated financial statements not misleading. They should be read in conjunction with the consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended December 31, 2021, as amended (our “Form 10-K”).
Use of Estimates	Use of Estimates The preparation of consolidated financial statements in accordance with GAAP requires us to make estimates and assumptions that affect the amounts reported and disclosed in the consolidated financial statements and the accompanying notes. Our estimates and assumptions consider the current macroeconomic trends and their implications of COVID-19 on our critical and significant accounting estimates. Actual results could differ materially from these estimates.
Recently Adopted Accounting Pronouncements	Significant Accounting Policies There have been no changes to our significant accounting policies from those disclosed in our Form 10-K. Recently Adopted Accounting Pronouncements In August 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2020-06, “Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity” (“ASU 2020-06”). The amendments in ASU 2020-06 simplify the accounting for convertible instruments by removing major separation models required under current GAAP. ASU 2020-06 removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exceptions and also requires the application of the if-converted method for calculating diluted earnings per share, whereas the treasury stock method is no longer permitted for convertible instruments. The standard is effective for public business entities, excluding entities eligible to be smaller reporting companies as defined by the SEC, for fiscal years and interim periods within those fiscal years, beginning after December 15, 2021. We adopted ASU 2020-06 on January 1, 2022 using the modified retrospective method of transition, which resulted in an increase in long-term debt of $26.4 million, a decrease in additional paid-in capital of $38.9 million and an increase to retained earnings of $12.5 million, as of January 1, 2022. Refer to Note 10, “Debt” for additional information.
Accounting Pronouncements Not Yet Adopted	Accounting Pronouncements Not Yet Adopted In October 2021, the FASB issued Accounting Standards Update No. 2021-08, “Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers” (“ASU 2021-08”), which requires contract assets and contract liabilities (deferred revenue) acquired in a business combination to be recognized and measured by the acquirer on the acquisition date in accordance with Accounting Standards Codification (“ASC”) 606, “Revenue from Contracts with Customers”, as if it had originated the contracts. The new guidance creates an exception to the general recognition and measurement principles of ASC 805, “Business Combinations”. The new standard should be applied prospectively and is effective for all public business entities for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. The standard is effective for all other entities for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted. We are currently evaluating the effects of the adoption of ASU 2021-08 on our consolidated financial statements. We do not believe that any other recently issued, but not yet effective accounting standards, if adopted, will have a material impact on our consolidated financial statements.
Revenue Recognition	Revenue Recognition We recognize revenue only when we satisfy an identified performance obligation (or bundle of obligations) by transferring control of a promised product or service to a customer. We consider a product or service to be transferred when a customer obtains control because a customer has sole possession of the right to use (or the right to direct the use of) the product or service for the remainder of its economic life or to consume the product or service in its own operations. We evaluate the transfer of control primarily from the customer’s perspective as this reduces the risk that revenue is recognized for activities that do not transfer control to the customer. The majority of our revenue is recognized over time because a customer continuously and simultaneously receives and consumes the benefits of our performance. The exceptions to this pattern are our sales of perpetual and term software licenses, and hardware, where we determined that a customer obtains control of the asset upon granting of access, delivery or shipment.

- Definition

The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-URI https://asc.fasb.org/topic&trid=2122394

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 105
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (d)(1)
-URI https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(iii)
-URI https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(4)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(ii)
-URI https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(i)
-URI https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (e)(1)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (d)(2)
-URI https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(iv)
-URI https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section S99
-Paragraph 5
-Subparagraph (SAB Topic 11.M.Q2)
-URI https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 4
-Subparagraph (e)(1)
-URI https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (h)(2)
-URI https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 4
-Subparagraph (e)(2)
-URI https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 848
-SubTopic 10
-Section 65
-Paragraph 1
-Subparagraph (e)(1)
-URI https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 65
-Paragraph 8
-Subparagraph (e)(2)
-URI https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section S99
-Paragraph 6
-URI https://asc.fasb.org/extlink&oid=122038215&loc=SL108384541-122693

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 10
-Section 65
-Paragraph 5
-Subparagraph (f)(1)
-URI https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (e)(2)
-URI https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (c)(2)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 10
-Section 65
-Paragraph 5
-Subparagraph (f)(3)
-URI https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (c)(1)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (e)(1)
-URI https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 65
-Paragraph 8
-Subparagraph (e)(1)
-URI https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (c)(3)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 926
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (f)(1)
-URI https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 926
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (f)(2)
-URI https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 926
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (f)(3)
-URI https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (e)(3)
-URI https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 848
-SubTopic 10
-Section 65
-Paragraph 2
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)(1)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(1)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 65
-Paragraph 8
-Subparagraph (e)(3)
-URI https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277

+ Details

Revenue from Contracts with Customers (Tables)

6 Months Ended

Jun. 30, 2022

Summary of Revenue Recognized on Various Performance Obligations and Elected Accounting Expedients

The breakdown of revenue recognized based on the origination of performance obligations and elected accounting expedients is presented in the tables below:


(In thousands)	Three Months Ended March 31, 2022		Three Months Ended June 30, 2022
Revenue related to deferred revenue balance at beginning of period	$	36,151	$	25,901
Revenue related to new performance obligations satisfied during the period		45,306		55,990
Revenue recognized under "right-to-invoice" expedient		61,114		68,877
Reimbursed travel expenses, shipping and other revenue		101		130
Total revenue	$	142,672	$	150,898


(In thousands)	Three Months Ended March 31, 2021		Three Months Ended June 30, 2021
Revenue related to deferred revenue balance at beginning of period	$	29,401	$	36,770
Revenue related to new performance obligations satisfied during the period		47,263		41,814
Revenue recognized under "right-to-invoice" expedient		56,811		62,105
Reimbursed travel expenses, shipping and other revenue		177		517
Total revenue	$	133,652	$	141,206

Summary of Changes in Estimate of Credit Losses for Contract Assets

Changes in the estimate of credit losses for contract assets are presented in the table below.


	Six Months Ended June 30,
(In thousands)	2022			2021
Beginning balance	$	2,110		$	2,110
Write-offs		(345	)		0
Ending balance	$	1,765		$	2,110
Less: Contract assets, short-term		564			576
Total contract assets, long-term	$	1,201		$	1,534

Revenue by Segment [Member]

Summary of Revenue by Type and Nature of Revenue Stream by Reportable Segments

The tables below summarize revenue by type and nature of revenue stream as well as by our reportable segment.


	Three Months Ended June 30, 2022
(In thousands)	Veradigm		Unallocated Amounts		Total
Provider	$	112,678	$	6,261	$	118,939
Payer & Life Sciences		31,959		0		31,959
Total revenue	$	144,637	$	6,261	$	150,898


	Three Months Ended June 30, 2021
(In thousands)	Veradigm		Unallocated Amounts		Total
Provider	$	108,147	$	7,757	$	115,904
Payer & Life Sciences		25,302		0		25,302
Total revenue	$	133,449	$	7,757	$	141,206


	Six Months Ended June 30, 2022
(In thousands)	Veradigm		Unallocated Amounts		Total
Provider	$	224,949	$	12,655	$	237,604
Payer & Life Sciences		55,966		0		55,966
Total revenue	$	280,915	$	12,655	$	293,570


	Six Months Ended June 30, 2021
(In thousands)	Veradigm		Unallocated Amounts		Total
Provider	$	212,035	$	15,039	$	227,074
Payer & Life Sciences		47,784		0		47,784
Total revenue	$	259,819	$	15,039	$	274,858

Accounts Receivable (Tables)

6 Months Ended

Jun. 30, 2022

Trade Accounts Receivable [Member]

Accounts Notes And Loans Receivable [Line Items]

Schedule of Changes in Estimate of Credit Losses for Trade Accounts Receivable

Changes in the estimate of credit losses for trade accounts receivable are presented in the table below.


	Six Months Ended June 30,
(In thousands)	2022			2021
Beginning balance	$	13,360		$	20,228
Current period provision		298			539
Write-offs		(1,077	)		(1,021	)
Ending balance	$	12,581		$	19,746

Leases (Tables)

6 Months Ended

Jun. 30, 2022

Lessee Disclosure [Abstract]

Summary of Operating Costs Associated with Leased Assets

Operating costs associated with leased assets are as follows:


(In thousands)	Three Months Ended June 30,						Six Months Ended June 30,
	2022			2021			2022			2021
Operating lease cost (1)	$	1,525		$	1,893		$	3,215		$	3,824
Less: Sublease income		(65	)		(74	)		(98	)		(157	)
Total operating lease costs	$	1,460		$	1,819		$	3,117		$	3,667

(1) Operating lease costs are recognized on a straight-line basis and are included in Selling, general and administrative expenses within the consolidated statements of operations.

Supplemental Cash Flow Information for Operating Leases

Supplemental cash flow information for operating leases is as follows:


(In thousands)	Six Months Ended June 30,
	2022		2021
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$	3,562	$	3,585
Right-of-use assets obtained in exchange for operating lease obligations	$	273	$	0

Summary of Balance Sheet Location and Balances for Operating Leases

The balance sheet location and balances for operating leases are as follows:


(In thousands, except lease term and discount rate)	June 30, 2022			December 31, 2021
Right-of-use assets - operating leases	$	15,904		$	18,324
Current operating lease liabilities	$	6,095		$	6,133
Long-term operating lease liabilities	$	13,873		$	16,754
Weighted average remaining lease term (in years)		4			5
Weighted average discount rate		3.3	%		3.4	%

Summary of Future Maturities of Lease and Non-Lease Components


	June 30, 2022
(In thousands)	Operating Leases
Remainder of 2022	$	3,318
2023		6,421
2024		3,706
2025		3,453
2026		2,835
Thereafter		1,581
Total lease liabilities		21,314
Less: Amount representing interest		(1,346	)
Less: Short-term lease liabilities		(6,095	)
Total Long-term lease liabilities	$	13,873

Business Combinations and Divestitures (Tables)

6 Months Ended

Jun. 30, 2022

Business Combinations [Abstract]

Schedule of Recognized Identified Assets Acquired and Liabilities Assumed


	(In thousands)
Cash and cash equivalents	$	472
Accounts receivable, net		394
Prepaid expenses and other current assets		206
Fixed assets		48
Intangible assets		7,280
Goodwill		17,542
Accounts payable and accrued expenses		(752	)
Deferred revenue		(675	)
Other liabilities		(5	)
Net assets acquired	$	24,510

Schedule Of estimated fair values of the identifiable intangible assets and their estimated useful lives

The following table summarizes the estimated fair values of the identifiable intangible assets and their estimated useful lives:


	Useful Life	Fair Value
Description	(In years)	(In thousands)
Customer Relationships	21	$	4,640
Technology	7		2,600
Tradenames	1		40
		$	7,280

Fair Value Measurements and Long-term Investments (Tables)

6 Months Ended

Jun. 30, 2022

Summary of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis

The following table summarizes our financial assets and liabilities measured at fair value on a recurring basis as of the respective balance sheet dates:


	Balance Sheet	June 30, 2022								December 31, 2021
(In thousands)	Classifications	Level 1		Level 2		Level 3		Total		Level 1		Level 2		Level 3		Total
Foreign exchange derivative assets	Prepaid expenses and other current assets	$	0	$	0	$	0	$	0	$	0	$	352	$	0	$	352
Total assets		$	0	$	0	$	0	$	0	$	0	$	352	$	0	$	352

Foreign exchange derivative assets	Accrued expenses	$	0	$	54	$	0	$	54	$	0	$	0	$	0	$	0
Contingent consideration - current	Accrued expenses		0		0		0		0		0		0		19		19
Total liabilities		$	0	$	54	$	0	$	54	$	0	$	0	$	19	$	19

Summary of Changes in Assets and Liability Measured at Fair Value on Recurring Basis

The changes in our Level 3 liability measured at fair value on a recurring basis at June 30, 2022 is summarized as follows:


(In thousands)	Contingent Consideration
Balance at December 31, 2021	$	19
Payments		(19	)
Balance at June 30, 2022	$	0

Long-Term Equity and Cost Method Investments [Member]

Summary of Long-term Equity Investments Included in Other Assets

The following table summarizes our long-term equity investments which are included in Other assets in the accompanying consolidated balance sheets:


	Number of Investees		Original		Carrying Value at
(In thousands, except for number of investees)	at June 30, 2022		Cost		June 30, 2022		December 31, 2021
Equity method investments (1)		4	$	7,099	$	11,579	$	12,260
Cost with adjustments		7		47,114		49,109		49,293
Total long-term equity investments		11	$	54,213	$	60,688	$	61,553

(1) Allscripts share of the earnings of our equity method investees is reported based on a one quarter lag.

Stockholders' Equity (Tables)

6 Months Ended

Jun. 30, 2022

Equity [Abstract]

Share-Based Compensation Expense


	Three Months Ended June 30,				Six Months Ended June 30,
(In thousands)	2022		2021		2022		2021
Cost of revenue:
Provider	$	221	$	220	$	538	$	496
Payer & Life Sciences		37		49		25		106
Total cost of revenue		258		269		563		602
Selling, general and administrative expenses		8,309		2,335		13,798		4,888
Research and development		596		938		1,726		2,006
Total stock-based compensation expense	$	9,163	$	3,542	$	16,087	$	7,496

Share-Based Awards Granted

We granted stock-based awards as follows:


	Three Months Ended June 30, 2022				Six Months Ended June 30, 2022
			Weighted-Average				Weighted-Average
			Grant Date				Grant Date
(In thousands, except per share amounts)	Shares		Fair Value		Shares		Fair Value
Service-based restricted stock units		1,221	$	18.41		1,246	$	18.44
Performance-based restricted stock units with a service condition		243	$	18.56		243	$	18.56
Market-based restricted stock units with a service condition		258	$	21.90		258	$	21.90
		1,722	$	18.95		1,747	$	18.97

Earnings (Loss) Per Share (Tables)

6 Months Ended

Jun. 30, 2022

Earnings Per Share [Abstract]

Calculations of Earnings (Loss) Per Share

The calculations of earnings (loss) per share are as follows:


	Three Months Ended June 30,						Six Months Ended June 30,
(In thousands, except per share amounts)	2022			2021			2022			2021
Basic earnings (loss) per Common Share:
Income from continuing operations, net of tax	$	3,262		$	26,143		$	21,733		$	30,443
(Loss) income from discontinued operations, net of tax		(67,288	)		(4,217	)		(62,902	)		540
Net (loss) income	$	(64,026	)	$	21,926		$	(41,169	)	$	30,983

Weighted-average common shares outstanding		114,251			136,647			115,052			138,409

Basic earnings from continuing operations per Common Share	$	0.03		$	0.19		$	0.19		$	0.22
Basic (loss) earnings from discontinued operations per Common Share		(0.59	)		(0.03	)		(0.55	)		0.00
Net (loss) earnings per Common Share	$	(0.56	)	$	0.16		$	(0.36	)	$	0.22

Diluted earnings (loss) per Common Share:
Income from continuing operations, net of tax	$	3,262		$	26,143		$	21,733		$	30,443
Effect of assumed conversions:
Plus: Interest expense, net of tax, associated with 0.875% Convertible Senior Notes		507			0			1,013			0
Income from continuing operations, net of tax after the effect of assumed conversions	$	3,769		$	26,143		$	22,746		$	30,443

(Loss) income from discontinued operations, net of tax	$	(67,288	)	$	(4,217	)	$	(62,902	)	$	540

Weighted-average common shares outstanding		114,251			136,647			115,052			138,409
Plus: Dilutive effect of restricted stock unit awards, convertible notes and warrants		4,452			8,624			21,670			8,839
Weighted-average common shares outstanding assuming dilution		118,703			145,271			136,722			147,248

Diluted earnings from continuing operations per Common Share	$	0.03		$	0.18		$	0.17		$	0.21
Diluted (loss) earnings from discontinued operations per Common Share		(0.57	)		(0.03	)		(0.46	)		0.00
Net (loss) earnings per Common Share	$	(0.54	)	$	0.15		$	(0.29	)	$	0.21

Anti-Dilutive Stock Options, Restricted Stock Unit Awards and Warrants Excluded from Computation of Diluted Earnings (Loss) Per Share


	Three Months Ended June 30,				Six Months Ended June 30,
(In thousands)	2022		2021		2022		2021
Shares subject to anti-dilutive restricted stock unit awards, convertible notes and warrants excluded from calculation		15,814		1,502		92		1,501

Goodwill and Intangible Assets (Tables)

6 Months Ended

Jun. 30, 2022

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill and Intangible Assets

Goodwill and intangible assets consist of the following:


	June 30, 2022							December 31, 2021
	Gross							Gross
	Carrying		Accumulated			Intangible		Carrying		Accumulated			Intangible
(In thousands)	Amount		Amortization			Assets, Net		Amount		Amortization			Assets, Net
Intangibles subject to amortization:
Proprietary technology	$	252,083	$	(230,757	)	$	21,326	$	249,483	$	(227,408	)	$	22,075
Customer contracts and relationships		402,125		(326,241	)		75,884		397,445		(321,830	)		75,615
Total	$	654,208	$	(556,998	)	$	97,210	$	646,928	$	(549,238	)	$	97,690

Intangibles not subject to amortization:
Registered trademarks						$	52,000						$	52,000
Goodwill							524,149							506,607
Total						$	576,149						$	558,607

Changes in Carrying Amount of Goodwill

Changes in the carrying amounts of goodwill by reportable segment for the six months ended June 30, 2022 were as follows:


(In thousands)	Veradigm		Unallocated		Total
Balance as of December 31, 2021		467,630		38,977		506,607
Additions		17,542		0		17,542
Balance as of June 30, 2022	$	485,172	$	38,977	$	524,149

- Definition

Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (h)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (g)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (e)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1A
-URI https://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 2
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267

Reference 11: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 55
-Paragraph 24
-URI https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268

Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

+ Details

Debt (Tables)

6 Months Ended

Jun. 30, 2022

Debt Instrument [Line Items]

Debt Outstanding Excluding Lease Obligations

Debt outstanding, excluding lease obligations, consists of the following:


	June 30, 2022							December 31, 2021
(In thousands)	Principal Balance		Unamortized Discount and Debt Issuance Costs		Net Carrying Amount			Principal Balance		Unamortized Discount and Debt Issuance Costs			Net Carrying Amount
0.875% Convertible Senior Notes (1)	$	207,911	$	4,104	$	203,807		$	167,853	$	(9,057	)	$	176,910
Senior Secured Credit Facility		0		3,912		(3,912	)		175,000		1,848			173,152
Total debt	$	207,911	$	8,016	$	199,895		$	342,853	$	(7,209	)	$	350,062

Interest Expense

Interest expense consists of the following:


	Three Months Ended June 30,				Six Months Ended June 30,
(In thousands)	2022		2021		2022		2021
Interest expense	$	1,084	$	1,079	$	2,590	$	2,367
Amortization of discounts and debt issuance costs		803		1,870		1,433		3,725
Total interest expense	$	1,887	$	2,949	$	4,023	$	6,092

Summary of Future Debt Payment Obligations

The following table summarizes future debt principal payment obligations as of June 30, 2022:



(In thousands)	Total		Remainder of 2022		2023		2024		2025		2026		Thereafter
0.875% Convertible Senior Notes (1)	$	207,911	$	0	$	0	$	0	$	0	$	0	$	207,911
Total debt	$	207,911	$	0	$	0	$	0	$	0	$	0	$	207,911

(1) Amount represents the face value of the 0.875% Convertible Senior Notes.

Income Taxes (Tables)

6 Months Ended

Jun. 30, 2022

Income Tax Disclosure [Abstract]

Effective Tax Rates

The effective tax rates were as follows:


	Three Months Ended June 30,						Six Months Ended June 30,
(In thousands, except effective tax rate)	2022			2021			2022			2021
(Loss) income from continuing operations before income taxes	$	(5,317	)	$	30,311		$	(1,267	)	$	35,717
Income tax benefit (provision)	$	8,579		$	(4,168	)	$	23,000		$	(5,274	)
Effective tax rate		161.4	%		13.8	%	NM				14.8	%

NM - We define “NM” as not meaningful for percentages greater than 200%.

Derivative Financial Instruments (Tables)

6 Months Ended

Jun. 30, 2022

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Fair Value and Balance Sheet Locations

The following tables provide information about the fair values of our derivative financial instruments as of the respective balance sheet dates:

June 30, 2022

Asset Derivatives

Liability Derivatives

(In thousands)

Balance Sheet Location

Fair Value

Balance Sheet Location

Fair Value

Derivatives qualifying as cash flow hedges:

Foreign exchange contracts

Prepaid expenses and other current assets

0

Accrued expenses

54

Total derivatives

0

54

December 31, 2021

Asset Derivatives

Liability Derivatives

(In thousands)

Balance Sheet Location

Fair Value

Balance Sheet Location

Fair Value

Derivatives qualifying as cash flow hedges:

Foreign exchange contracts

Prepaid expenses and other current assets

352

Accrued expenses

0

Total derivatives

352

-

Derivatives Instruments Designated as Cash Flow Hedges


	Amount of Gain (Loss) Recognized in OCI							Amount of Gain (Loss) Reclassified from AOCI into Income
(In thousands)	Three Months Ended June 30, 2022			Six Months Ended June 30, 2022			Location of Gain (Loss) Reclassified from AOCI into Income	Three Months Ended June 30, 2022			Six Months Ended June 30, 2022
Foreign exchange contracts	$	(155	)	$	(303	)	Cost of Revenue	$	(1	)	$	36
							Selling, general and administrative expenses		0			24
							Research and development	$	(1	)	$	42


	Amount of Gain (Loss) Recognized in OCI						Amount of Gain (Loss) Reclassified from AOCI into Income
(In thousands)	Three Months Ended June 30, 2021			Six Months Ended June 30, 2021		Location of Gain (Loss) Reclassified from AOCI into Income	Three Months Ended June 30, 2021		Six Months Ended June 30, 2021
Foreign exchange contracts	$	(54	)	$	121	Cost of Revenue	$	290	$	611
						Selling, general and administrative expenses		167		351
						Research and development	$	317	$	668

Accumulated Other Comprehensive Loss (Tables)

6 Months Ended

Jun. 30, 2022

Equity [Abstract]

Components of Accumulated Other Comprehensive Loss

Changes in the balances of each component included in AOCI are presented in the tables below. All amounts are net of tax.


(In thousands)	Foreign Currency Translation Adjustments			Unrealized Net Gains (Losses) on Foreign Exchange Contracts			Total
Balance as of December 31, 2021 (1)	$	(3,026	)	$	261		$	(2,765	)
Other comprehensive (loss) income before reclassifications		(867	)		(226	)		(1,093	)
Net losses (gains) reclassified from accumulated other comprehensive loss		0			(76	)		(76	)
Net other comprehensive income (loss)		(867	)		(302	)		(1,169	)
Balance as of June 30, 2022 (2)	$	(3,893	)	$	(41	)	$	(3,934	)

(1) Net of taxes of $91 thousand for unrealized net gains on foreign exchange contract derivatives.

(2) Net of taxes of $14 thousand for unrealized net losses on foreign exchange contract derivatives.


(In thousands)	Foreign Currency Translation Adjustments			Unrealized Net Gains (Losses) on Foreign Exchange Contracts			Total
Balance as of December 31, 2020 (1)	$	(2,957	)	$	1,119		$	(1,838	)
Other comprehensive income (loss) before reclassifications		520			90			610
Net (gains) losses reclassified from accumulated other comprehensive loss		0			(1,209	)		(1,209	)
Net other comprehensive income (loss)		520			(1,119	)		(599	)
Balance as of June 30, 2021	$	(2,437	)	$	0		$	(2,437	)

(1) Net of taxes of $390 thousand for unrealized net gains on foreign exchange contract derivatives.

Income Tax Effects Related to Components of Other Comprehensive Income (Loss)

The following tables reflect the tax effects allocated to each component of other comprehensive income (loss) (“OCI”):


	Three Months Ended June 30,
	2022									2021
(In thousands)	Before-Tax Amount			Tax Effect			Net Amount			Before-Tax Amount			Tax Effect		Net Amount
Foreign currency translation adjustments	$	(717	)	$	0		$	(717	)	$	421		$	0	$	421
Derivatives qualifying as cash flow hedges:
Foreign exchange contracts:
Net (losses) gains arising during the period		(155	)		39			(116	)		(54	)		14		(40	)
Net losses (gains) reclassified into income		2			(1	)		1			(774	)		200		(574	)
Net change in unrealized (losses) gains on foreign exchange contracts		(153	)		38			(115	)		(828	)		214		(614	)
Other comprehensive (loss) income	$	(870	)	$	38		$	(832	)	$	(407	)	$	214	$	(193	)


	Six Months Ended June 30,
	2022								2021
(In thousands)	Before-Tax Amount			Tax Effect		Net Amount			Before-Tax Amount			Tax Effect			Net Amount
Foreign currency translation adjustments	$	(867	)	$	0	$	(867	)	$	520		$	0		$	520
Derivatives qualifying as cash flow hedges:
Foreign exchange contracts:
Net (losses) gains arising during the period		(303	)		77		(226	)		121			(31	)		90
Net (gains) losses reclassified into income		(101	)		25		(76	)		(1,630	)		421			(1,209	)
Net change in unrealized (losses) gains on foreign exchange contracts		(404	)		102		(302	)		(1,509	)		390			(1,119	)
Other comprehensive (loss) income	$	(1,271	)	$	102	$	(1,169	)	$	(989	)	$	390		$	(599	)

Discontinued Operations (Tables)

6 Months Ended

Jun. 30, 2022

Summary of Discontinued Operations in Financial Statements


(In thousands)	June 30, 2022		December 31, 2021
Carrying amounts of major classes of assets associated with Hospitals and Large Physician Practices included as part of discontinued operations:
Cash and cash equivalents	$	20,000	$	55,834
Restricted cash		0		861
Accounts receivable, net of allowance of $16,584 as of December 31, 2021		0		155,447
Contract assets, net of allowance of $492 as of December 31, 2021		0		61,382
Prepaid expenses and other current assets		0		58,431
Total current assets attributable to discontinued operations		20,000		331,955

Fixed assets, net		0		38,083
Software development costs, net		0		97,416
Intangible assets, net		0		86,240
Goodwill		0		467,871
Deferred taxes, net		0		6,607
Contract assets - long-term, net of allowance of $739 as of December 31, 2021		0		28,623
Right-of-use assets - operating leases		0		50,585
Other assets		0		17,731
Total long-term assets attributable to discontinued operations	$	0	$	793,156

Carrying amounts of major classes of liabilities associated with Hospitals and Large Physician Practices included as part of discontinued operations:

Accounts payable	$	30,372	$	11,555
Accrued expenses		0		38,007
Accrued compensation and benefits		0		61,167
Deferred revenue		0		205,152
Current operating lease liabilities		0		13,466
Total current liabilities attributable to discontinued operations		30,372		329,347

Deferred revenue long-term		0		2,568
Long-term operating lease liabilities		0		48,068
Other liabilities		0		270
Total long-term liabilities attributable to discontinued operations	$	0	$	50,906


	Three Months Ended June 30,						Six Months Ended June 30,
(In thousands)	2022			2021			2022			2021
Major income and expense line items related to Hospitals and Large Physician Practices:
Revenue:
Provider	$	70,569		$	232,508		$	284,799		$	467,208
Total revenue		70,569			232,508			284,799			467,208
Cost of revenue:
Provider		45,806			149,175			189,498			296,747
Total cost of revenue		45,806			149,175			189,498			296,747
Gross profit		24,763			83,333			95,301			170,461
Selling, general and administrative expenses		19,782			50,966			68,531			100,511
Research and development		8,130			30,277			31,986			58,790
Asset impairment charges		0			5,072			0			5,072
Amortization of intangible assets		88			3,461			3,538			6,921
Loss from discontinued operations for Hospitals and Large Physician Practices		(3,237	)		(6,443	)		(8,754	)		(833	)
Other (loss) income, net		(484	)		229			12			468
Gain on sale of discontinued operations		2,765			0			2,765			0
Equity in net (loss) income of unconsolidated investments		(76	)		0			(76	)		0
Loss from discontinued operations for Hospitals and Large Physician Practices before income taxes		(1,032	)		(6,214	)		(6,053	)		(365	)
Income tax (provision) benefit		(66,256	)		1,976			(56,849	)		420
(Loss) income from discontinued operations, net of tax for Hospitals and Large Physician Practices	$	(67,288	)	$	(4,238	)	$	(62,902	)	$	55

EPSi and CarePort [Member]

Summary of Discontinued Operations in Financial Statements


	Three Months Ended			Six Months Ended
(In thousands)	June 30, 2021			June 30, 2021
Major income and expense line items related to EPSi and CarePort:
Revenue:
Provider	$	368		$	0
Total revenue		368			0
Cost of revenue:
Provider		316			(48	)
Total cost of revenue		316			(48	)
Gross profit		52			48
Selling, general and administrative expenses		9			74
Research and development		8			(32	)
Income from discontinued operations for EPSi and CarePort		35			6
Other income, net		1			1
Gain on sale of discontinued operations		0			647
Income from discontinued operations for EPSi and CarePort before income taxes		36			654
Income tax provision		(15	)		(169	)
Income from discontinued operations, net of tax for EPSi and CarePort	$	21		$	485

- Definition

Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3A
-URI https://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5D
-URI https://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 11
-URI https://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3A
-URI https://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4B
-URI https://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5C
-URI https://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5A
-URI https://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-URI https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4A
-URI https://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760

+ Details

Business Segments (Tables)

6 Months Ended

Jun. 30, 2022

Segment Reporting [Abstract]

Revenues and Income (Loss) from Operations Related to Segment Within Reconciliation to Consolidated Amounts


	Three Months Ended June 30,						Six Months Ended June 30,
(In thousands)	2022			2021			2022			2021
Revenue:
Veradigm	$	144,637		$	133,449			280,915			259,819
Unallocated Amounts		6,261			7,757			12,655			15,039
Total revenue	$	150,898		$	141,206		$	293,570		$	274,858

Gross profit:
Veradigm	$	75,409		$	63,641			144,604			122,264
Unallocated Amounts		4,073			4,778			8,359			9,072
Total gross profit	$	79,482		$	68,419		$	152,963		$	131,336

Income (loss) from operations:
Veradigm	$	23,974		$	18,014			42,089			29,508
Unallocated Amounts		(29,330	)		(1,196	)		(40,873	)		(4,961	)
Total (loss) income from operations	$	(5,356	)	$	16,818		$	1,216		$	24,547

Supplemental Disclosures (Tables)

6 Months Ended

Jun. 30, 2022

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Supplemental Disclosures

The majority of the restricted cash balance as of June 30, 2022 and 2021 represents lease deposits.


	June 30,
(In thousands)	2022		2021
Reconciliation of cash, cash equivalents and restricted cash:
Cash and cash equivalents	$	500,164	$	159,556
Restricted cash		1,307		1,307
Total cash, cash equivalents and restricted cash	$	501,471	$	160,863

	Six Months Ended June 30,
(In thousands)	2022		2021
Supplemental non-cash information:
Issuance of treasury stock to commercial partner	$	0	$	534

Basis of Presentation and Significant Accounting Policies - Additional Information (Detail) - USD ($) $ in Thousands	Jun. 30, 2022	Jan. 01, 2022	Dec. 31, 2021
Basis Of Presentation And Significant Accounting Policies [Line Items]
Long-term Debt		$ 26,400
Additional paid-in capital		38,900
Retained earnings	$ 738,864	$ 12,500	$ 767,556
Accounting Standards Update 2020-06 [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Change in Accounting Principle, Accounting Standards Update, Adopted [true false]	true
Change in Accounting Principle, Accounting Standards Update, Adoption Date	Jan. 01, 2022
Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]	true

- Definition

Indicates (true false) whether accounting standards update was adopted.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 10
-Section 65
-Paragraph 5
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 20
-Section 65
-Paragraph 5
-URI https://asc.fasb.org/extlink&oid=121483254&loc=SL120254523-199619

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 10
-Section 65
-Paragraph 5
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 4
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 10
-Section 65
-Paragraph 5
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 65
-Paragraph 8
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 4
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 926
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 926
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 65
-Paragraph 7
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 65
-Paragraph 7
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 65
-Paragraph 5
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 65
-Paragraph 5
-URI https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=122640432&loc=SL120254519-210437

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 10
-Section 65
-Paragraph 4
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=128293352&loc=SL120154346-209984

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 848
-SubTopic 10
-Section 65
-Paragraph 1
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 65
-Paragraph 3
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 65
-Paragraph 3
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (a)(1)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 3
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=122640432&loc=SL120320025-210437

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 105
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 848
-SubTopic 10
-Section 65
-Paragraph 2
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 3
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=122640432&loc=SL120320025-210437

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 105
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (a)(2)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 832
-SubTopic 10
-Section 65
-Paragraph 1
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232

+ Details

- Definition

Date accounting standards update was adopted, in YYYY-MM-DD format.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (a)(1)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 65
-Paragraph 7
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 832
-SubTopic 10
-Section 65
-Paragraph 1
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 65
-Paragraph 5
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 4
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 65
-Paragraph 3
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 3
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=122640432&loc=SL120320025-210437

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 105
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 105
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 3
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=122640432&loc=SL120320025-210437

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 926
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 65
-Paragraph 7
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (a)(2)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (a)(3)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 848
-SubTopic 10
-Section 65
-Paragraph 1
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 10
-Section 65
-Paragraph 5
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 10
-Section 65
-Paragraph 5
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 65
-Paragraph 3
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 10
-Section 65
-Paragraph 4
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=128293352&loc=SL120154346-209984

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 65
-Paragraph 8
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 65
-Paragraph 3
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 848
-SubTopic 10
-Section 65
-Paragraph 2
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 20
-Section 65
-Paragraph 5
-URI https://asc.fasb.org/extlink&oid=121483254&loc=SL120254523-199619

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 4
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 926
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=122640432&loc=SL120254519-210437

Reference 36: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 65
-Paragraph 5
-URI https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497

Reference 37: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 10
-Section 65
-Paragraph 5
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984

+ Details

- Definition

Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.

+ References + Details

Revenue from Contracts with Customers - Additional Information (Detail) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2022 USD ($)	Jun. 30, 2021 USD ($)	Jun. 30, 2022 USD ($) Revenue_Stream	Jun. 30, 2021 USD ($)	Dec. 31, 2021 USD ($)
Disaggregation of Revenue [Line Items]
Number of primary revenue streams \| Revenue_Stream			2
Total unsatisfied performance obligations	$ 923.0		$ 923.0
Selling, General and Administrative Expenses [Member]
Disaggregation of Revenue [Line Items]
Capitalized Contract Cost Amortization	2.9	$ 2.9	5.8	$ 6.2
Prepaid Expenses and Other Current Assets [Member]
Disaggregation of Revenue [Line Items]
Capitalized Contract Cost, Gross	10.2		10.2		$ 8.1
Other Assets [Member]
Disaggregation of Revenue [Line Items]
Capitalized Contract Cost, Gross	$ 11.9		$ 11.9

Revenue from Contracts with Customers - Summary of Revenue Recognized on Various Performance Obligations and Elected Accounting Expedients (Detail) - USD ($) $ in Thousands	3 Months Ended				6 Months Ended
	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2022	Jun. 30, 2021
Revenue from Contract with Customer [Abstract]
Revenue related to deferred revenue balance at beginning of period	$ 25,901	$ 36,151	$ 36,770	$ 29,401
Revenue related to new performance obligations satisfied during the period	55,990	45,306	41,814	47,263
Revenue recognized under "right-to-invoice" expedient	68,877	61,114	62,105	56,811
Reimbursed travel expenses, shipping and other revenue	130	101	517	177
Total revenue	$ 150,898	$ 142,672	$ 141,206	$ 133,652	$ 293,570	$ 274,858

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 924
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-URI https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856

+ Details

Revenue from Contracts with Customers - Summary of Revenue by Type and Nature of Revenue Stream by Reportable Segments (Detail) - USD ($) $ in Thousands	3 Months Ended				6 Months Ended
	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2022	Jun. 30, 2021
Disaggregation Of Revenue [Line Items]
Total revenue	$ 150,898	$ 142,672	$ 141,206	$ 133,652	$ 293,570	$ 274,858
Unallocated Amounts [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	6,261		7,757		12,655	15,039
Veradigm [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	144,637		133,449		280,915	259,819
Veradigm [Member] \| Operating Segments [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	144,637		133,449		280,915	259,819
Provider [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	118,939		115,904		237,604	227,074
Provider [Member] \| Unallocated Amounts [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	6,261		7,757		12,655	15,039
Provider [Member] \| Veradigm [Member] \| Operating Segments [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	112,678		108,147		224,949	212,035
Payer & Life Sciences
Disaggregation Of Revenue [Line Items]
Total revenue	31,959		25,302		55,966	47,784
Payer & Life Sciences \| Unallocated Amounts [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	0		0		0	0
Payer & Life Sciences \| Veradigm [Member] \| Operating Segments [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	$ 31,959		$ 25,302		$ 55,966	$ 47,784

- Definition

+ References

+ Details

Revenue from Contracts with Customers - Summary of Changes in Estimate of Credit Losses for Contract Assets (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Revenue from Contract with Customer [Abstract]
Beginning Balance	$ 2,110	$ 2,110
Write-offs	345	0
Ending balance	1,765	2,110
Less: Contract assets, short-term	564	576	$ 576
Total contract assets, long-term	$ 1,201	$ 1,534	$ 1,534

Accounts Receivable - Schedule of Changes in Estimate of Credit Losses for Trade Accounts Receivable (Detail) - Trade Accounts Receivable [Member] - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Accounts Notes And Loans Receivable [Line Items]
Beginning Balance	$ 13,360	$ 20,228
Current period provision	298	539
Write-offs	(1,077)	(1,021)
Ending Balance	$ 12,581	$ 19,746

Leases - Additional Information (Detail) - Maximum [Member]	6 Months Ended
	Jun. 30, 2022
Lessee Lease Description [Line Items]
Operating leases, remaining lease terms	5 years
Operating leases, options to extend leases term	5 years
Operating leases, options to terminate leases term	1 year

Leases - Summary of Operating Costs Associated with Leased Assets (Detail) - USD ($)
$ in Thousands

3 Months Ended

6 Months Ended

Jun. 30, 2022

Jun. 30, 2021

Jun. 30, 2022

Jun. 30, 2021

Leases [Abstract]

Operating lease cost

^[1]

$ 1,525

$ 1,893

$ 3,215

$ 3,824

Less: Sublease income

(65)

(74)

(98)

(157)

Total operating lease costs

$ 1,460

$ 1,819

$ 3,117

$ 3,667

[1]	Operating lease costs are recognized on a straight-line basis and are included in Selling, general and administrative expenses within the consolidated statements of operations

Leases - Supplemental Cash Flow Information for Operating Leases (Detail) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Leases [Abstract]
Operating cash flows from operating leases	$ 3,562	$ 3,585
Right-of-use assets obtained in exchange for operating lease obligations	$ 273	$ 0

Leases - Summary of Balance Sheet Location and Balances for Operating Leases (Detail) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Leases [Abstract]
Right-of-use assets - operating leases	$ 15,904	$ 18,324
Current operating lease liabilities	6,095	6,133
Long-term operating lease liabilities	$ 13,873	$ 16,754
Weighted average remaining lease term (in years)	4 years	5 years
Weighted average discount rate	3.30%	3.40%

Leases - Summary of Future Maturities of Lease and Non-Lease Components (Detail) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Operating Leases [Abstract]
Operating Leases, Remainder of 2022	$ 3,318
Operating Leases, 2023	6,421
Operating Leases, 2024	3,706
Operating Leases, 2025	3,453
Operating Leases, 2026	2,835
Operating Leases, Thereafter	1,581
Operating Leases, Total lease liabilities	21,314
Operating Leases, Less: Amount representing interest	(1,346)
Operating Leases, Less: Short-term lease liabilities	(6,095)	$ (6,133)
Operating Leases, Total Long-term lease liabilities	$ 13,873	$ 16,754

Business Combinations and Divestitures - Additional Information (Detail) - USD ($) $ in Thousands							3 Months Ended		6 Months Ended	12 Months Ended
	May 02, 2022	Mar. 25, 2022	Aug. 23, 2021	Dec. 31, 2020	Oct. 29, 2020	Oct. 15, 2020	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2022	Dec. 31, 2021
Business Acquisition [Line Items]
Business combination, acquisition related costs									$ 200
Cash		$ 24,500
Purchase price in cash		24,000
Intangible assets							$ 7,280		7,280
Goodwill							524,149		524,149	$ 506,607
Deferred taxes, net							10,861		10,861	16,625
2bPrecise [Member]
Business Acquisition [Line Items]
Pre-tax gain (loss) on sale of business			$ 8,400
CarePort Purchase Agreement [Member]
Business Acquisition [Line Items]
Pre-tax gain (loss) on sale of business										$ 600
CarePort Purchase Agreement [Member] \| WellSky Corp [Member]
Business Acquisition [Line Items]
Pre-tax gain (loss) on sale of business				$ 933,900
Sale of business unit				1,350,000
CarePort Purchase Agreement [Member] \| WellSky Corp [Member] \| Senior Secured Term Loan [Member] \| Second Amended Credit Agreement [Member]
Business Acquisition [Line Items]
Prepayment of debt				$ 161,000
EPSi Purchase Agreement [Member] \| Strata Decision Technology LLC [Member]
Business Acquisition [Line Items]
Pre-tax gain (loss) on sale of business						$ 222,600
Sale of business unit						$ 365,000
EPSi Purchase Agreement [Member] \| Strata Decision Technology LLC [Member] \| Senior Secured Term Loan [Member] \| Second Amended Credit Agreement [Member]
Business Acquisition [Line Items]
Prepayment of debt					$ 19,000
Hospitals and Large Physician Practices business [Member]
Business Acquisition [Line Items]
Pre-tax gain (loss) on sale of business							$ 2,800		$ 2,800
Babel Health [Member]
Business Acquisition [Line Items]
Total consideration for Babel Health		$ 24,000
Harris Dawn Holdings Inc. [Member]
Business Acquisition [Line Items]
Sale of business unit	$ 670,000
Additional cash	$ 30,000
American College of Cardiology [Member]
Business Acquisition [Line Items]
Date of acquisition								Mar. 25, 2022

Business Combinations and Divestitures - Schedule of Assets Acquired and Liabilities Assumed (Detail) $ in Thousands	6 Months Ended
	Jun. 30, 2022 USD ($)
Business Combinations [Abstract]
Cash and cash equivalents	$ 472
Accounts receivable, net	394
Prepaid expenses and other current assets	206
Fixed assets	48
Intangible assets	7,280
Goodwill	17,542
Accounts payable and accrued expenses	752
Deferred revenue	675
Other liabilities	5
Net assets acquired	$ 24,510

Business Combinations and Divestitures - Schedule of Acquired Intangible Assets Amortization (Detail) $ in Thousands	6 Months Ended
	Jun. 30, 2022 USD ($)
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	$ 7,280
Trade Names [Member]
Business Acquisition [Line Items]
Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life	1 year
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	$ 40
Customer Relationships [Member]
Business Acquisition [Line Items]
Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life	21 years
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	$ 4,640
Technology [Member]
Business Acquisition [Line Items]
Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life	7 years
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	$ 2,600

Fair Value Measurements and Long-term Investments - Summary of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Prepaid expenses and other current assets	$ 91,521	$ 60,511
Total assets	0	352
Total liabilities	54	19
Level 1 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total assets	0	0
Total liabilities	0	0
Level 2 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total assets	0	352
Total liabilities	54	0
Level 3 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total assets	0	0
Total liabilities	0	19
Foreign exchange derivative assets [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Prepaid expenses and other current assets	0	352
Accrued expenses	54	0
Foreign exchange derivative assets [Member] \| Level 1 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Prepaid expenses and other current assets	0	0
Accrued expenses	0	0
Foreign exchange derivative assets [Member] \| Level 2 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Prepaid expenses and other current assets	0	352
Accrued expenses	54	0
Foreign exchange derivative assets [Member] \| Level 3 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Prepaid expenses and other current assets	0	0
Accrued expenses	0	0
Contingent Consideration Current [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Accrued expenses	0	19
Contingent Consideration Current [Member] \| Level 1 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Accrued expenses	0	0
Contingent Consideration Current [Member] \| Level 2 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Accrued expenses	0	0
Contingent Consideration Current [Member] \| Level 3 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Accrued expenses	$ 0	$ 19

Fair Value Measurements and Long-term Investments - Summary of Changes in Liability Measured at Fair Value on Recurring Basis (Detail) - Fair Value, Inputs, Level 3 [Member] - Contingent Consideration [Member] $ in Thousands	6 Months Ended
	Jun. 30, 2022 USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Balance at December 31, 2021	$ 19
Payments	(19)
Balance at June 30, 2022	$ 0

Fair Value Measurements and Long-term Investments - Summary of Long-term Equity Investments Included in Other Assets (Detail)
$ in Thousands

6 Months Ended

Jun. 30, 2022

USD ($)

Investment

Dec. 31, 2021

USD ($)

Fair Value Disclosures [Abstract]

Equity method investments, Number of Investees | Investment

^[1]

Cost with adjustments, Number of investees | Investment

Total long-term equity investments, Number of Investees | Investment

Equity method investments, Original Cost

^[1]

$ 7,099

Cost with adjustments, Original Cost

47,114

Total long-term equity investments, Original Cost

54,213

Equity method investments, Carrying Value

^[1]

11,579

$ 12,260

Cost with adjustments, Carrying Value

49,109

49,293

Total long-term equity investments, Carrying Value

$ 60,688

$ 61,553

[1]	Allscripts share of the earnings of our equity method investees is reported based on a one quarter lag.

Fair Value Measurements and Long-term Investments - Additional Information (Detail) - USD ($) shares in Thousands, $ in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Impairment of long-term investments	$ 0
Third-party Cost Method Investments [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Conversion of notes into shares		475
Third-party Cost Method Investments [Member] \| Other Income (Loss), Net [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Gain on note conversion and revaluation of existing investment		$ 9,700

Stockholders' Equity - Additional Information (Detail) - USD ($)				3 Months Ended		6 Months Ended		12 Months Ended
	Jan. 24, 2022	May 26, 2021	Nov. 18, 2020	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Class Of Stock [Line Items]
Capitalized stock-based compensation costs				$ 0	$ 0	$ 0	$ 0
Stock options granted						0	0
Share issued, exercise of options and release of stock awards						2,500,000		2,200,000
Shares settled for tax withholding						1,300,000	895,000
Common stock repurchased, amount						$ 143,372,000	$ 308,953,000
2020 Stock Purchase Program [Member]
Class Of Stock [Line Items]
Common stock repurchased, amount					$ 101,500,000		$ 101,500,000
Common stock repurchased, shares					5,600,000	1,600,000	5,600,000
Common stock available to repurchase			$ 300,000,000
2021 Stock Purchase Program [Member]
Class Of Stock [Line Items]
Common stock repurchased, amount					$ 202,900,000
Common stock repurchased, shares					11,500,000	9,100,000
Common stock available to repurchase		$ 350,000,000
Previous Program [Member]
Class Of Stock [Line Items]
Common stock repurchased, amount				93,700,000
Accelerated Share Repurchase Agreement [Member]
Class Of Stock [Line Items]
Shares of common stock yet to be repurchased, amount				$ 106,800,000		$ 106,800,000
Two Thousand Twenty Two Stock Purchase Program
Class Of Stock [Line Items]
Common stock repurchased, amount						$ 143,400,000
Common stock repurchased, shares				5,500,000		7,800,000
Common stock available to repurchase	$ 250,000,000

Stockholders' Equity - Stock-Based Compensation Expense (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense	$ 9,163	$ 3,542	$ 16,087	$ 7,496
Cost of revenue [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense	258	269	563	602
Cost of revenue [Member] \| Provider [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense	221	220	538	496
Cost of revenue [Member] \| Payer & Life Sciences
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense	37	49	25	106
Selling, General and Administrative Expenses [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense	8,309	2,335	13,798	4,888
Research and development [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense	$ 596	$ 938	$ 1,726	$ 2,006

Stockholders' Equity - Stock-Based Awards Granted (Detail) - $ / shares shares in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2022
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares, granted	1,722	1,747
Weighted-Average Grant Date Fair Value, granted	$ 18.95	$ 18.97
Service-Based Restricted Stock Units [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares, granted	1,221	1,246
Weighted-Average Grant Date Fair Value, granted	$ 18.41	$ 18.44
Performance-Based Restricted Stock Units with a Service Condition [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares, granted	243	243
Weighted-Average Grant Date Fair Value, granted	$ 18.56	$ 18.56
Market-Based Restricted Stock Units with a Service Condition [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares, granted	258	258
Weighted-Average Grant Date Fair Value, granted	$ 21.90	$ 21.90

Earnings (Loss) Per Share - Calculations of Earnings (Loss) Per Share (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Basic earnings (loss) per Common Share:
Income from continuing operations, net of tax	$ 3,262	$ 26,143	$ 21,733	$ 30,443
(Loss) income from discontinued operations, net of tax	(67,288)	(4,217)	(62,902)	540
Net (loss) income	$ (64,026)	$ 21,926	$ (41,169)	$ 30,983
Weighted-average common shares outstanding	114,251	136,647	115,052	138,409
Basic earnings from continuing operations per Common Share	$ 0.03	$ 0.19	$ 0.19	$ 0.22
Basic (loss) earnings from discontinued operations per Common Share	(0.59)	(0.03)	(0.55)	0.00
Net (loss) earnings per Common Share - Basic	$ (0.56)	$ 0.16	$ (0.36)	$ 0.22
Diluted earnings (loss) per Common Share:
Income from continuing operations	$ 3,262	$ 26,143	$ 21,733	$ 30,443
Plus: Interest expense, net of tax, associated with 0.875% Convertible Senior Notes	507	0	1,013	0
Income (loss) from continuing operations, net of tax after the effect of assumed conversions	3,769	26,143	22,746	30,443
(Loss) income from discontinued operations, net of tax	$ (67,288)	$ (4,217)	$ (62,902)	$ 540
Weighted-average common shares outstanding	114,251	136,647	115,052	138,409
Plus: Dilutive effect of restricted stock unit awards, convertible notes and warrants	4,452	8,624	21,670	8,839
Weighted-average common shares outstanding assuming dilution	118,703	145,271	136,722	147,248
Diluted earnings from continuing operations per Common Share	$ 0.03	$ 0.18	$ 0.17	$ 0.21
Diluted (loss) earnings from discontinued operations per Common Share	(0.57)	(0.03)	(0.46)	0.00
Net (loss) earnings per Common Share - Diluted	$ (0.54)	$ 0.15	$ (0.29)	$ 0.21

Earnings (Loss) Per Share - Anti-Dilutive Stock Options, Restricted Stock Unit Awards and Warrants Excluded from Computation of Diluted Earnings (Loss) Per Share (Detail) - shares shares in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Earnings Per Share [Abstract]
Shares subject to anti-dilutive restricted stock unit awards and warrants excluded from calculation	15,814	1,502	92	1,501

Goodwill and Intangible Assets - Goodwill and Intangible Assets (Detail) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Schedule Of Goodwill And Intangible Assets [Line Items]
Gross Carrying Amount	$ 654,208	$ 646,928
Accumulated Amortization	(556,998)	(549,238)
Intangible Assets, Net	97,210	97,690
Registered trademarks	52,000	52,000
Goodwill	524,149	506,607
Total	576,149	558,607
Proprietary Technology [Member]
Schedule Of Goodwill And Intangible Assets [Line Items]
Gross Carrying Amount	252,083	249,483
Accumulated Amortization	(230,757)	(227,408)
Intangible Assets, Net	21,326	22,075
Customer Contracts and Relationships [Member]
Schedule Of Goodwill And Intangible Assets [Line Items]
Gross Carrying Amount	402,125	397,445
Accumulated Amortization	(326,241)	(321,830)
Intangible Assets, Net	$ 75,884	$ 75,615

- Definition

Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.

+ References + Details

Goodwill and Intangible Assets - Changes in Carrying Amount of Goodwill (Detail) $ in Thousands	6 Months Ended
	Jun. 30, 2022 USD ($)
Goodwill [Line Items]
Goodwill	$ 506,607
Additions	17,542
Goodwill	524,149
Veradigm [Member] \| Operating Segments [Member]
Goodwill [Line Items]
Goodwill	467,630
Additions	17,542
Goodwill	485,172
Unallocated [Member] \| Operating Segments [Member]
Goodwill [Line Items]
Goodwill	38,977
Additions	0
Goodwill	$ 38,977

- Definition

+ References + Details

Goodwill and Intangible Assets - Additional Information (Detail) - USD ($)	Jun. 30, 2022	Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Accumulated impairment losses associated with goodwill	$ 0	$ 0

Debt - Debt Outstanding Excluding Lease Obligations (Detail) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Debt Instrument [Line Items]
Debt instrument principal amount	$ 207,911	$ 342,853
Unamortized Discount and Debt Issuance Costs	8,016	(7,209)
Net Carrying Amount	199,895	350,062
0.875% Convertible Senior Notes [Member]
Debt Instrument [Line Items]
Debt instrument principal amount	207,911	167,853
Unamortized Discount and Debt Issuance Costs	4,104	(9,057)
Net Carrying Amount	203,807	176,910
Senior Secured Credit Facility [Member]
Debt Instrument [Line Items]
Debt instrument principal amount	0	175,000
Unamortized Discount and Debt Issuance Costs	3,912	1,848
Net Carrying Amount	$ (3,912)	$ 173,152

Debt - Debt Outstanding Excluding Lease Obligations (Parenthetical) (Detail) - USD ($) $ in Thousands	Jun. 30, 2022	Jan. 01, 2022	Dec. 31, 2021	Dec. 31, 2019
Debt Instrument [Line Items]
Long-Term Debt, Gross	$ 207,911		$ 342,853
0.875% Convertible Senior Notes [Member]
Debt Instrument [Line Items]
Debt instrument principal amount	207,900		207,911	$ 218,000
Long-Term Debt, Gross	$ 207,911		167,853
Additional Paid-In Capital [Member] \| 0.875% Convertible Senior Notes [Member]
Debt Instrument [Line Items]
Debt Instrument, Convertible, Carrying Amount of Equity Component		$ 40,100	$ 40,058	$ 40,100

Debt - Interest Expense (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
Debt - Interest Expense (Detail) - USD ($) $ in Thousands	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Debt Instrument [Line Items]
Total interest expense	$ 1,887	$ 2,949	$ 4,023	$ 6,092
Convertible Senior Notes and Senior Secured Credit Facility [Member]
Debt Instrument [Line Items]
Interest expense	1,084	1,079	2,590	2,367
Amortization of discounts and debt issuance costs	803	1,870	1,433	3,725
Total interest expense	$ 1,887	$ 2,949	$ 4,023	$ 6,092

Debt - Interest Expense Related to 0.875% Convertible Senior Notes (Detail) - 0.875% Convertible Senior Notes [Member] - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Debt Instrument [Line Items]
Coupon interest	$ 455	$ 455	$ 910	$ 910
Amortization of discounts and debt issuance costs	228	1,474	456	2,933
Total interest expense related to the 0.875% Convertible Senior Notes	$ 683	$ 1,929	$ 1,366	$ 3,843

Debt - Additional Information (Detail) - USD ($) $ in Thousands		1 Months Ended
	Jan. 01, 2022	Jun. 30, 2020	Dec. 31, 2019	Jun. 30, 2022	Apr. 29, 2022	Dec. 31, 2021
Debt Instrument [Line Items]
Debt instrument principal amount				$ 207,911		$ 342,853
Additional paid-in capital	$ 38,900
Long term debt	26,400
Retained Earnings (Accumulated Deficit)	12,500			738,864		767,556
Senior Secured Credit Facility [Member]
Debt Instrument [Line Items]
Debt instrument principal amount				0		175,000
0.875% Convertible Senior Notes [Member]
Debt Instrument [Line Items]
Debt instrument principal amount				207,911		167,853
Debt instrument principal amount			$ 218,000	$ 207,900		207,911
Additional paid-in capital	38,900
Long term debt	26,400
Interest rate		0.875%	0.875%	0.875%
Debt issuance costs			$ 700
Percentage of interest rate used to to compute the initial fair value of the liability component			1.95%
Debt instrument, initial fair value of liability component			$ 177,900
Retained Earnings (Accumulated Deficit)	12,500
Debt instrument, net carrying value of equity component				$ 16,400
Payments for repurchase debt instrument		$ 7,700
Debt instrument aggregate principal amount repurchased		10,100
Gain on repurchase of debt instrument		500
Proceeds due to termination of capped call transaction		300
Reduction to capped call fees		800
Loss in capped call		$ 500
0.875% Convertible Senior Notes [Member] \| Additional Paid-In Capital [Member]
Debt Instrument [Line Items]
Debt instrument, equity component amount	40,100		40,100			$ 40,058
Payments of capped call fees			17,200
Debt discounts and issuance costs	$ 1,100		$ 1,100
Revolving credit facility [Member]
Debt Instrument [Line Items]
Available for the issuance of letters of credit					$ 50,000
Borrowing Capacity					700,000
Available for swingline loans					25,000
Credit facility borrowed under certain foreign currencies					$ 100,000
Letters of credit outstanding				800
Credit facility, amount available borrowing capacity				$ 699,200

Debt - Summary of Future Debt Payment Obligations (Detail)
$ in Thousands

Jun. 30, 2022

USD ($)

Debt Instrument [Line Items]

$ 207,911

207,911

0.875% Convertible Senior Notes [Member]

Debt Instrument [Line Items]

Total

207,911

^[1]

^[1]

^[1]

^[1]

^[1]

^[1]

$ 207,911

^[1]

[1]	Amount represents the face value of the 0.875% Convertible Senior Notes.

Debt - Summary of Future Debt Payment Obligations (Parenthetical) (Detail)	Jun. 30, 2022	Jun. 30, 2020	Dec. 31, 2019
0.875% Convertible Senior Notes [Member]
Debt Instrument [Line Items]
Interest rate	0.875%	0.875%	0.875%

Income Taxes - Effective Tax Rates (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Income Tax Disclosure [Abstract]
(Loss) income from continuing operations before income taxes	$ (5,317)	$ 30,311	$ (1,267)	$ 35,717
Income tax benefit (provision)	$ (8,579)	$ 4,168	$ (23,000)	$ 5,274
Effective tax rate	161.40%	13.80%		14.80%

- Definition

Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 940
-SubTopic 20
-Section 25
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(10))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(8))
-URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 235
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-URI https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(15))
-URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

+ Details

- Definition

Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.

+ References + Details

Income Taxes - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Mar. 31, 2022	Dec. 31, 2021
Income Loss From Operations Before Provision Benefit For Income Taxes [Line Items]
Windfall benefit			$ 11.2	$ 4.6
Pretax Income	$ 4.1	$ 5.4		$ 35.7
Cumulative operating income loss period considered			3 years
Valuation allowance	11.2		$ 11.2
Unrecognized income tax benefits	$ 30.5		30.5			$ 30.3
Deferred tax assets					$ 7.0
Domestic Deferred Tax Assets [Member]
Income Loss From Operations Before Provision Benefit For Income Taxes [Line Items]
Valuation allowance			$ 11.2

Derivative Financial Instruments - Fair Value and Balance Sheet Locations (Detail) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Derivatives Fair Value [Line Items]
Derivative asset, fair value	$ 0	$ 352
Derivative liability, fair value	54	0
Designated as Hedging Instrument [Member] \| Foreign Exchange Contract [Member] \| Prepaid Expenses and Other Current Assets [Member]
Derivatives Fair Value [Line Items]
Derivative asset, fair value	0	352
Designated as Hedging Instrument [Member] \| Foreign Exchange Contract [Member] \| Accrued expenses [Member]
Derivatives Fair Value [Line Items]
Derivative liability, fair value	$ 54	$ 0

Derivative Financial Instruments - Additional Information (Detail) - Foreign Exchange Forward Contracts [Member] ₨ in Millions, $ in Millions	6 Months Ended
	Jun. 30, 2022 INR (₨) Number	Jun. 30, 2022 USD ($) Number
Derivative [Line Items]
Number of contracts \| Number	6	6
Derivative notional amount outstanding	₨ 50	$ 0.6
Foreign Currency Cash Flow Gain Loss To Be Reclassified During Specified Period \| $		$ 0.1
Estimated period of unrealized losses included in AOCI reclassified into income	12 months
Maximum [Member]
Derivative [Line Items]
Date of contracts mature	Dec. 31, 2022
Minimum [Member]
Derivative [Line Items]
Date of contracts mature	Jul. 31, 2022

Derivative Financial Instruments - Derivatives Instruments Designated as Cash Flow Hedges (Detail) - Cash Flow Hedging [Member] - Foreign Exchange Contract [Member] - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Derivative Instruments Gain Loss [Line Items]
Amount of Gain (Loss) Recognized in OCI	$ (155)	$ (54)	$ (303)	$ 121
Cost of revenue [Member]
Derivative Instruments Gain Loss [Line Items]
Amount of Gain (Loss) Reclassified from AOCI into Income	(1)	290	36	611
Selling, General and Administrative Expenses [Member]
Derivative Instruments Gain Loss [Line Items]
Amount of Gain (Loss) Reclassified from AOCI into Income	0	167	24	351
Research and development [Member]
Derivative Instruments Gain Loss [Line Items]
Amount of Gain (Loss) Reclassified from AOCI into Income	$ (1)	$ 317	$ 42	$ 668

Accumulated Other Comprehensive Loss - Components of Accumulated Other Comprehensive Loss (Detail) - USD ($)
$ in Thousands

3 Months Ended

6 Months Ended

Jun. 30, 2022

Jun. 30, 2021

Jun. 30, 2022

Jun. 30, 2021

Accumulated Other Comprehensive Income Loss [Line Items]

Balance at the beginning of the period

$ 1,408,138

Other comprehensive (loss) income before reclassifications

(1,093)

$ 610

Net losses (gains) reclassified from accumulated other comprehensive loss

(76)

(1,209)

Total other comprehensive income (loss)

$ (832)

$ (193)

(1,169)

(599)

Balance at the end of the period

1,196,348

Foreign Currency Translation Adjustments [Member]

Accumulated Other Comprehensive Income Loss [Line Items]

Balance at the beginning of the period

(3,026)

^[1]

(2,957)

^[2]

Other comprehensive (loss) income before reclassifications

(867)

520

Net losses (gains) reclassified from accumulated other comprehensive loss

Total other comprehensive income (loss)

(867)

520

Balance at the end of the period

(3,893)

^[3]

(2,437)

(3,893)

^[3]

(2,437)

Derivatives Qualifying as Cash Flow Hedges [Member] | Foreign Exchange Contract [Member]

Accumulated Other Comprehensive Income Loss [Line Items]

Balance at the beginning of the period

261

^[1]

1,119

^[2]

Other comprehensive (loss) income before reclassifications

(226)

Net losses (gains) reclassified from accumulated other comprehensive loss

(76)

(1,209)

Total other comprehensive income (loss)

(302)

(1,119)

Balance at the end of the period

^[3]

Accumulated Other Comprehensive Loss [Member]

Accumulated Other Comprehensive Income Loss [Line Items]

Balance at the beginning of the period

(2,765)

^[1]

(1,838)

^[2]

Balance at the end of the period

$ (3,934)

^[3]

$ (2,437)

$ (3,934)

^[3]

$ (2,437)

[1]	Net of taxes of $91 thousand for unrealized net gains on foreign exchange contract derivatives.
[2]	Net of taxes of $390 thousand for unrealized net gains on foreign exchange contract derivatives.
[3]	Net of taxes of $14 thousand for unrealized net losses on foreign exchange contract derivatives.

- Definition

Amount after tax and reclassification adjustments of other comprehensive income (loss).

+ References

+ Details

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 55
-Paragraph 10
-URI https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

+ Details

Accumulated Other Comprehensive Loss - Components of Accumulated Other Comprehensive Loss (Parenthetical) (Detail) - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2021	Dec. 31, 2020
Foreign Exchange Contract [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Revaluation of tax effects	$ 14	$ 91	$ 390

Accumulated Other Comprehensive Loss - Income Tax Effects Related to Components of Other Comprehensive Income (Loss) (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Accumulated Other Comprehensive Income Loss [Line Items]
Foreign currency translation adjustments, Before-Tax Amount	$ (717)	$ 421	$ (867)	$ 520
Foreign currency translation adjustments, Tax Effect	0	0	0	0
Foreign currency translation adjustments, Net	(717)	421	(867)	520
Other comprehensive (loss) income before income tax benefit	(870)	(407)	(1,271)	(989)
Other comprehensive income (loss), Tax effect	38	214	102	390
Total other comprehensive income (loss)	(832)	(193)	(1,169)	(599)
Derivatives Qualifying as Cash Flow Hedges [Member] \| Foreign Exchange Contract [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Derivatives qualifying as cash flow hedges, net (losses) gains arising during the period, Before-Tax, Amount	(155)	(54)	(303)	121
Derivatives qualifying as cash flow hedges, net gains (losses) arising during the period, Tax Effect	39	14	77	(31)
Derivatives qualifying as cash flow hedges, net gains (losses) arising during the period, Net	(116)	(40)	(226)	90
Derivatives qualifying as cash flow hedges, net losses (gains) reclassified into income, Before-Tax Amount	2	(774)	(101)	(1,630)
Derivatives qualifying as cash flow hedges, net (gains) losses reclassified into income, Tax Effect	(1)	200	25	421
Derivatives qualifying as cash flow hedges, net losses (gains) reclassified into income, Net	1	(574)	(76)	(1,209)
Derivatives qualifying as cash flow hedges, net change in unrealized (losses) gains on foreign exchange contracts, Before-Tax Amount, Total	(153)	(828)	(404)	(1,509)
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax	38	214	102	390
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent, Total	$ (115)	$ (614)	(302)	(1,119)
Total other comprehensive income (loss)			$ (302)	$ (1,119)

Contingencies - Additional Information (Detail) - Practice Fusion, Inc. [Member] - USD ($)			12 Months Ended
	Apr. 05, 2022	Mar. 18, 2022	Dec. 31, 2020
Loss Contingencies [Line Items]
Litigation settlement, amount	$ 200,000,000
Deferred Prosecution Agreement [Member]
Loss Contingencies [Line Items]
Increase (Decrease) in Other Deferred Liability		$ 200,000
Criminal Fine [Member] \| US Department of Justice and US Attorney [Member]
Loss Contingencies [Line Items]
Litigation settlement, amount			$ 25,300,000
Forfeiture Payment [Member] \| US Department of Justice and US Attorney [Member]
Loss Contingencies [Line Items]
Litigation settlement, amount			959,700
Civil Settlements [Member] \| US Department of Justice and US Attorney [Member]
Loss Contingencies [Line Items]
Litigation settlement, amount			118,600,000
State Medicaid Program Expenditures [Member] \| US Department of Justice and US Attorney [Member]
Loss Contingencies [Line Items]
Litigation settlement, amount			$ 5,200,000

Discontinued Operations - Additional Information (Detail)	6 Months Ended
	Jun. 30, 2022 Business Segment
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of reportable segments \| Segment	2
EPSi and CarePort [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of businesses sold \| Business	2

Discontinued Operations - Summary of Major Classes of Assets and Liabilities as Reported on Consolidated Balance Sheets (Detail) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021	Jun. 30, 2021
Carrying amounts of major classes of assets associated with Hospitals and Large Physician Practices included as part of discontinued operations:
Cash and cash equivalents	$ 500,164	$ 132,517	$ 159,556
Assets, Current	828,767	761,342
Total current assets attributable to discontinued operations	20,000	331,955
Carrying amounts of major classes of liabilities associated with Hospitals and Large Physician Practices included as part of discontinued operations:
Total current liabilities attributable to discontinued operations	30,372	329,347
Hospitals and Large Physician Practice [Member]
Carrying amounts of major classes of assets associated with Hospitals and Large Physician Practices included as part of discontinued operations:
Cash and cash equivalents	20,000	55,834
Restricted Cash	0	861
Accounts receivable, net of allowance of $16,584 as of December 31, 2021	0	155,447
Contract assets, net of allowance of $492 as of December 31, 2021	0	61,382
Prepaid expenses and other current assets	0	58,431
Total current assets attributable to discontinued operations	20,000	331,955
Fixed assets, net	0	38,083
Software development costs, net	0	97,416
Intangible assets, net	0	86,240
Goodwill	0	467,871
Deferred taxes, net	0	6,607
Contract assets - long-term, net of allowance of $739 as of December 31, 2021	0	28,623
Right-of-use assets - operating leases	0	50,585
Other assets	0	17,731
Total long-term assets attributable to discontinued operations	0	793,156
Carrying amounts of major classes of liabilities associated with Hospitals and Large Physician Practices included as part of discontinued operations:
Accounts payable	30,372	11,555
Accrued expenses	0	38,007
Accrued compensation and benefits	0	61,167
Deferred revenue	0	205,152
Current operating lease liabilities	0	13,466
Total current liabilities attributable to discontinued operations	30,372	329,347
Deferred revenue long-term	0	2,568
Long-term operating lease liabilities	0	48,068
Other liabilities	0	270
Total long-term liabilities attributable to discontinued operations	$ 0	$ 50,906

Discontinued Operations - Summary of Major Classes of Assets and Liabilities as Reported on Consolidated Balance Sheets (Parenthetical) (Detail) - Hospital And Large Physician Practices [Member] $ in Thousands	Dec. 31, 2021 USD ($)
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Disposal group including discontinued operation accounts receivable, allowance	$ 16,584
Disposal group including discontinued operation contract asset, allowance current	492
Disposal group including discontinued operation contract asset - long term, allowance	$ 739

Discontinued Operations - Summary of Major Income and Expense Line Items Reported in Consolidated Statements of Operations (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Cost of revenue:
Asset impairment charges	$ 0	$ 172	$ 0	$ 172
Gain on sale of discontinued operations	2,765	0	2,765	647
Equity in net loss of unconsolidated investments	(207)	(86)	(605)	(64)
(Loss) income from discontinued operations before income taxes	(3,797)	(6,178)	(8,818)	(358)
Income tax (provision) benefit	(66,256)	1,961	(56,849)	251
(Loss) income from discontinued operations, net of tax	(67,288)	(4,217)	(62,902)	540
Hospital And Large Physician Practices [Member]
Revenue:
Total revenue	70,569	232,508	284,799	467,208
Cost of revenue:
Total cost of revenue	45,806	149,175	189,498	296,747
Gross profit (loss)	24,763	83,333	95,301	170,461
Selling, general and administrative expenses	19,782	50,966	68,531	100,511
Research and development	8,130	30,277	31,986	58,790
Asset impairment charges	0	5,072	0	5,072
Amortization of intangible assets	88	3,461	3,538	6,921
Income (loss) from discontinued operations	(3,237)	(6,443)	(8,754)	(833)
Other (loss) income, net	(484)	229	12	468
Gain on sale of discontinued operations	2,765	0	2,765	0
Equity in net loss of unconsolidated investments	(76)	0	(76)	0
(Loss) income from discontinued operations before income taxes	(1,032)	(6,214)	(6,053)	(365)
Income tax (provision) benefit	(66,256)	1,976	(56,849)	420
(Loss) income from discontinued operations, net of tax	(67,288)	(4,238)	(62,902)	55
EPSi and CarePort [Member]
Revenue:
Total revenue		368		0
Cost of revenue:
Total cost of revenue		316		(48)
Gross profit (loss)		52		48
Selling, general and administrative expenses		9		74
Research and development		8		(32)
Income (loss) from discontinued operations		35		6
Other (loss) income, net		1		1
Gain on sale of discontinued operations		0		647
(Loss) income from discontinued operations before income taxes		36		654
Income tax (provision) benefit		(15)		(169)
(Loss) income from discontinued operations, net of tax		21		485
Provider [Member] \| Hospital And Large Physician Practices [Member]
Revenue:
Total revenue	70,569	232,508	284,799	467,208
Cost of revenue:
Total cost of revenue	$ 45,806	149,175	$ 189,498	296,747
Provider [Member] \| EPSi and CarePort [Member]
Revenue:
Total revenue		368		0
Cost of revenue:
Total cost of revenue		$ 316		$ (48)

Business Segments - Additional Information (Detail)		6 Months Ended
Business Segments - Additional Information (Detail)	Jan. 01, 2022 Segment	Jun. 30, 2022 Revenue_Stream Segment
Segment Reporting [Abstract]
Number of primary revenue streams \| Revenue_Stream		2
Number of operating segments	3
Number of reportable segments		2

Business Segments - Revenues and Income (Loss) from Operations Related to Segment Within Reconciliation to Consolidated Amounts (Detail) - USD ($) $ in Thousands	3 Months Ended				6 Months Ended
	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2022	Jun. 30, 2021
Segment Reporting Information [Line Items]
Revenue	$ 150,898	$ 142,672	$ 141,206	$ 133,652	$ 293,570	$ 274,858
Gross profit	79,482		68,419		152,963	131,336
Income (loss) from operations	(5,356)		16,818		1,216	24,547
Unallocated Amounts [Member]
Segment Reporting Information [Line Items]
Revenue	6,261		7,757		12,655	15,039
Gross profit	4,073		4,778		8,359	9,072
Income (loss) from operations	(29,330)		(1,196)		(40,873)	(4,961)
Veradigm [Member]
Segment Reporting Information [Line Items]
Revenue	144,637		133,449		280,915	259,819
Gross profit	75,409		63,641		144,604	122,264
Income (loss) from operations	$ 23,974		$ 18,014		$ 42,089	$ 29,508

- Definition

Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 18: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1,2)
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Supplemental Disclosures - Supplemental Disclosures (Detail) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Reconciliation of cash, cash equivalents and restricted cash:
Cash and cash equivalents	$ 500,164	$ 159,556	$ 132,517
Restricted cash	1,307	1,307	$ 1,308
Total cash, cash equivalents and restricted cash	501,471	160,863
Supplemental non-cash information:
Issuance of treasury stock to commercial partner	$ 0	$ 534